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1. Summary  
 
The A Disintegrin And Metalloproteinase with Thrombospondin Motif (ADAMTS) family is a family 
of extracellular metalloproteinases involved in the degradation and reorganization of the 
extracellular matrix (ECM). These proteinases play important roles during embryogenesis, wound 
healing and cancer progression. During cancer progression the degradation of the ECM by 
proteinases is a key step allowing cancer cells to leave the primary tumor site and invade the 
surrounding tissue.   
ADAMTS16 is a poorly characterized family member but although nothing is known about its 
substrates or its mechanism of action, several studies showed that ADAMTS16 plays a role during 
renal and gonadal development. In addition to its role during embryogenesis, ADAMTS16 has 
been implicated in blood pressure regulation. Moreover, several studies linked ADAMTS16 
expression to cancer progression and metastasis. Thus, ADAMTS16 is well-connected to 
morphogenesis and human diseases, but without knowledge of its characteristics, substrates, 
and the molecular pathways in which it participates. 
We developed an assay using a decellularized ECM and liquid chromatography–mass 
spectrometry (LC-MS/MS) to identify substrates of ADAMTS16 and to gain further insights into 
its mechanism of action. Using this approach we identified fibronectin (FN) as a substrate of 
ADAMTS16.  
FN is one of the most abundant proteins within the ECM. FN fibers allow binding and 
fibrillogenesis of other ECM proteins such as fibrillins, collagens, tenascin-C and TGFβ-binding 
proteins and are therefore important components for the formation of an intact ECM. We 
showed that cleavage of FN near its N-terminus by ADAMTS16, leads to inhibition of FN fibril 
maturation, thereby having a strong impact on ECM assembly.  
Furthermore, we observed that ectopic ADAMTS16 expression in the epithelial cell line MDCKI 
strongly altered morphology when cultured in 3D collagen gels. MDCKI spheroids lacked FN in 
their matrix, resulting in smaller size and the formation of multiple lumina.  
FN is, however, not only important for ECM formation, but has a crucial role in cell adhesion, 
migration and cell signaling via binding to cell surface integrins. We could show that ADAMTS16 
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expression and the resulting cleavage of FN upregulates MMP3 expression in MDCKI cells, 
therefore creating an intriguing dual protease feed-forward loop that may serve to limit and fine-
tune FN assembly and control tubular morphogenesis. 
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2. Introduction 
 
2.1 The Extracellular Matrix  
 
The extracellular matrix (ECM) is a non-cellular structure that is present in all tissues and organs (Fig.2.1). 
It acts as a scaffold giving physical support and structure to tissues, organs and single cells. Additionally, 
the ECM actively modulates cellular responses such as cell migration, proliferation, differentiation and cell 
survival through complex biochemical and biomechanical cues 1. The ECM is composed of proteoglycans 
(e.g., decorin, perlecan and aggrecan) and glycoproteins (e.g., collagens, fibronectin, laminin and 
tenascin). A variety of ECM proteins share common structural motifs such as an Arg-Gly-Asp (RGD) motif, 
which allows their binding to the surface receptors of the integrin family 2, 3.   
Proteoglycans and glycoproteins form a tight network that allows binding and storage of various growth 
factors. Therefore the ECM controls their localization, function and presentation to the cells and provides 
binding sites for cell-surface receptors such as integrins and syndecans 2. Similar to soluble growth factors, 
the molecular composition and the physical properties of the matrix (e.g., stiffness, elasticity) can 
influence cell behavior and cell fate 3. The ECM thus has an important function in regulating the 
development, function and homeostasis of all eukaryotic cells. It not only regulates cell adhesion, but also 
actively influences cell signaling, not only by controlled release of growth factors, but also by changes in 
ECM stiffness and mechanical properties.   
The most abundant proteins within the ECM are members of the collagen family. Collagen makes up 30% 
of the total protein mass of a multicellular animal 1, 3.  There are 28 known collagens and these are the 
products of 49 distinct collagen α-chain gene products 4. Collagens assemble into tight right-handed triple 
helical pro-collagens with loose ends at their carboxy-terminus and their amino-terminus. Some collagen 
molecules are known to be homotrimers, whereas others assemble as heterotrimers that are comprised 
of two or three distinguishable α-chain types 3-6. After secretion the loose ends at the N- and C-terminus 
of pro-collagen molecules are cut off by specific proteinases, which leads to the formation of mature 
tropocollagen 7. Most collagens are so-called fibrillar collagens. After secretion several tropocollagen 
molecules bind to each other forming collagen fibrils, which in turn interact with each other, forming 
collagen bundles also called collagen fibers with a radius of several micrometers 8 (Fig.2.2).   
Other fibrous glycoproteins within the ECM are fibronectin (FN) and tenascin (TN). Their structures can 
be described as ‘beads-on-a-string’, since both consist of many small domains in a row, connected by short 
linker regions. In addition, both are glycoproteins, and both consist to a large part of fibronectin type III 
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domains 9. Opposite to FN, which is strongly adhesive, tenascins are generally anti-adhesive and strongly 
influence the adhesion of cells to other ECM proteins 10. There are four tenascins described thus far: 
tenascin-C, tenascin-W, tenascin-R, and tenascin-X 9, 11. The heptad domain at the N-terminus of each 
molecule is responsible for tenascin assembly into homo-trimers, which in the case of tenascin-C and 
tenascin-W can dimerize by disulfide bonds through their N-termini to homo-hexamers (Figure 2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Overview of the extracellular matrix (adapted from 12)  
The proteins, fibronectin, collagen, and laminin contain binding sites for one another, as well as binding 
sites for cell surface receptors such as integrins. The proteoglycans are huge protein polysaccharide 
complexes that occupy much of the volume of the extracellular space. 
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Figure 2.2: Overview of collagen assembly  
A.Three single α-chains form a triple helical pro-collagen molecule. After secretion the pro-peptide 
domains at the C-terminals and N-terminals are cleaved, resulting in formation of mature collagen, also 
called tropocollagen 7. B. The tropocollagen molecules than assemble into oligomeric collagen fibrils, 
which assemble into thick collagen fibers 13.  
 
 
 
 
 
 
 
 
 
Figure 2.3: Tenascin-C  
Overview of the domain organization of tenascine C 14. The electron micrograph of purified tenascin-C 
reveals its oligomerization into a hexamer 15.  
 
 
Proteoglycans, another important family of ECM proteins, consist of a core protein that is covalently 
bound to glycosaminoglycans (GAGs). The only exception within the proteoglycan family is hyaluronan 
(HA), which is made up entirely of GAGs therefore lacking the core protein. GAGs are long, unbranched 
sulfated polysaccharides with a highly negative charge. GAG chains consist of disaccharide repeating 
regions containing acetylated amino sugar moieties (N-acetyl-galactosamine or N-acetyl-glucosamine) 
and uronic acids (D-glucoronic acid or L-iduronic acid) 8, 16.  
The core proteins of proteoglycans can be divided into several subgroups depending on their location and 
binding: small leucine-rich proteoglycans (SLRP), modular proteoglycans (hyalectins and non-HA binding 
PGs), and cell-surface proteoglycans 16 (Fig. 2.4). The GAG chains tend to be very hydrophilic and stiff, 
A B 
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which is helpful in forming hydrogels that can withstand very high compressive forces. These properties 
are very important in the knee joint, where they act as natural lubricant 17.  
However, proteoglycans also contribute to other processes like cell adhesion, migration, and proliferation. 
One of the hyalectins, neurocan, is involved in the inhibition of neuronal attachment and neurite 
outgrowth 16. Another example is the SLRP decorin, which functions in signaling, as it can bind to multiple 
receptors. Moreover, decorin has been shown to inhibit transforming growth factor-β (TGF-β) receptor 
signaling. Several possible mechanisms have been postulated for the inhibitory effect of decorin on TGF-
β signalling, such as direct binding of decorin to TGF-β leading to inactivation and sequestration into the 
ECM 18.  Another possible mechanism for decorin-mediated interference with TGF-β signalling, is either 
through phosphorylation of Smad2 19, or low-density lipoprotein-related protein-1 (LRP-1), a known cell-
surface receptor for decorin 20. Additionally decorin can regulate the synthesis of other ECM proteins such 
as fibrillin-1, via binding and phosphorylation of insulin-like growth factor-I (IGF-I) receptor 16, 21, 22. Thus 
proteoglycans have a variety of different functions and are therefore important components of the 
ECM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Overview of the proteoglycan family (adapted from 16) 
Classification of proteoglycans based on their location and binding. The heterogeneous group of 
proteoglycans include small leucine-rich (SLRP; e.g., decorin) and modular proteoglycans. Modular 
proteoglycans are divided into hyalectans (hyaluronan- and lectin-binding proteoglycans) and the non-
hyaluronan-binding proteoglycans (perlecan and agrin) of the basement membrane. The third group of 
cell-surface proteoglycans are the membrane-spanning syndecans and the glycosylphosphatidylinositol-
anchored glypicans.   
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There are many other known ECM components which, together with the above mentioned proteins, make 
up the matrisome 23. The mammalian core matrisome includes all common ECM proteins and consists 
of approximately 300 proteins. There is also a large number of ECM-affiliated and ECM-modifying 
proteins that are not included in the core matrisome 23.   
As discussed above the ECM, is not just a simple scaffold for cell attachment, but plays a crucial role in cell 
signaling, adhesion and survival. Therefore the ECM has a highly dynamic structure that is consistently 
remodeled and its molecular components are subjected to a variety of post-translational modifications 1, 
5. Alterations in ECM turnover can lead to severe defects during embryogenesis and promote the 
development of various diseases such as the formation of solid tumors and cancer metastasis, 
osteoarthritis, atherosclerosis and fibrosis 3, 24-26. 
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2.2 The Basement Membrane  
 
The basement membrane (BM) is a specific type of ECM (Figure 2.5), which is always associated with cells 
and separates the epithelium from the stroma of any tissue. The BM provides structural support, divides 
tissues into compartments and regulates cellular behavior 27, 28. The BM constitutes of large insoluble 
molecules that form sheet-like structures via self-assembly, which is driven by cell-surface anchors and 
receptors 29-31. The main components of the BM are laminin, type IV collagen, heparan-sulfate 
proteoglycans (HSPGs)  and nidogen 27.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Schematic drawing of the basement membrane (adapted from 27) 
The basement membrane consists of several ECM proteins and is anchored to the receptors of 
neighboring cells. Laminin and collagen IV form independent networks that interact with each other and 
other ECM components.  
 
 
The most abundant proteins in the BM are laminin and collagen IV. The laminin structure is unique since 
the chains form a cross-like structure. Laminins consist of an α, β, and γ chain, making them heterotrimeric 
and quite diverse. At least 16 isoforms have been described so far (Fig. 2.6) 32. As already mentioned above 
laminins are one of the main components of the BM and are involved in cell-specific processes such as 
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proliferation and adhesion. Via ligand binding to cell membrane receptors, laminins can alter 
transcriptional levels of genes and even influence chromatin remodeling of the gene promoters. 
Moreover, polarization of cells upon interaction with laminins can affect their response to signaling from 
the extracellular space 32, 33.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Structure of laminins (adapted from 27)  
Overview of the structures of the laminin family of proteins, and the types of α, β, and γ chains that these 
ECM proteins consist of. 
 
 
Another main component of the BM is collagen IV. Along with laminin it plays an important role in cell 
adhesion, migration, differentiation and growth 28, 34. Type IV collagen is ubiquitously present in all BMs 
independent of the tissue. It is also called the 'network-forming collagen', due to its capacity to self-
assemble into organized networks (Fig. 2.7). This property makes it different from the fibrillar collagens 
(types I, II and III collagen), which need an already formed network, mainly fibronectin, to assembly into 
fibrils 27. Each type IV collagen α-chain consists of three domains: an N-terminal 7S domain, a middle triple-
helical domain, and a C-terminal globular non-collagenous (NC1) domain. It is assumed that the six α-
chains of type IV collagen self-assemble to form predominantly three sets of triple-helical molecules that 
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self-associate via their NC1 domains and their middle triple-helical regions to form spider web-like 
scaffolds which interact with the laminin network and form a basic BM scaffold 35, 36.  
Various studies have shown that type IV collagen network formation is crucial for BM stability and 
assembly 37, 38. Mutations in the type IV collagen α3-chain and α5-chain have been associated with 
Goodpasture syndrome and Alport syndrome 27, 39-42.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Type IV collagen network formation (adapted from 27) 
All of the type IV collagen in mammals is derived from six genetically distinct -chain polypeptides. The 
-chains can be separated into three domains: an N-terminal 7S domain, a middle triple-helical domain, 
and a C-terminal globular non-collagenous (NC1) domain. The assembly of a particular trimer begins when 
the three NC1 domains initiate a molecular interaction. The next step in the assembly is the type IV 
collagen dimer formation. Two type IV collagen protomers associate via their NC1 trimers to form an NC1 
hexamer. Next, four protomers interact at the glycosylated amino-terminal 7S region to form tetramers. 
These interactions form the nucleus for a type IV collagen scaffold.    
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2.3 Fibronectin 
 
Fibronectin (FN) is a multidomain glycoprotein, which connects the cells to the surrounding ECM and BM 
via integrin binding 43. Furthermore FN is an important binding partner for other ECM proteins such as 
collagens, tenascins, fibrillins and latent-transforming growth factor beta-binding proteins (LTBPs), which 
need an intact FN network that serves as a template for their own fibril formation 44-47. Therefore FN plays 
an important role for the development of an intact mature ECM.  
In addition to its structural importance, FN mediates a variety of cellular interactions with the ECM and 
plays important roles in cell adhesion, migration, growth and differentiation 48.  FN is widely expressed by 
multiple cell types. Consistent with its observed impact on ECM ontogeny, cell adhesion and migration, 
inactivation of the Fn1 gene in mice leads to embryonic lethality by 8.5 days of gestation, with embryos 
showing impaired cardiovascular development and other morphogenetic defects 49.  
FN is usually secreted as a dimeric glycoprotein composed of two nearly identical subunits that range in 
size from 230 kDa to 270 kDa. The two subunits are covalently linked near their C-terminus by a pair of 
disulfide bonds. Variation in subunit size are primarily the results of alternative splicing 50, 51. Although FN 
molecules are the product of a single gene, alternative splicing of a single pre-mRNA can generate as many 
as 20 variants in human FN 48.  
FN is composed of three different types of modules namely type I, II, and III repeats. Type I repeats are 
about 40 amino-acid residues in length and contain two disulfide bonds; type II repeats comprise a stretch 
of approximately 60 amino acids and two intrachain disulfide bonds; type III repeats have a 7-stranded β-
barrel structure without any disulfide bonds and can therefore undergo conformational changes 52, 53. 
These modules contain functional domains that mediate interactions with other ECM proteins, cell surface 
receptors and FN itself 54.  
FN can be subdivided into two major forms, based on its solubility. The soluble plasma FN and the less 
soluble cellular FN. Plasma FN is synthesized predominantly in the liver by hepatocytes and shows a 
relatively simple splicing pattern where the extra type III repeats EIIIA and EIIIB are missing (Fig. 2.8). The 
V region (also called IIICS in human FN) is included in the majority of cellular FN subunits, but is only 
present in one subunit of each plasma FN dimer 48, 54. EIIIA and the V region are both known to have an 
effect on cell adhesion. In fact, both the EIIIA and the V region have a direct role in cell adhesion by binding 
to α4 and α9 integrins 55 56. In addition to integrin binding the V region is essential for FN dimer secretion 
57. The function of the EIIIB is not yet properly understood although it may have an effect in cell adhesion 
as well 43, 54. Cellular FN consists of a much larger and more heterogeneous group of FN isoforms that 
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result from cell-type-specific and species-specific splicing patterns. Thus, alternative splicing of precursor 
mRNA from the single FN gene has the capacity to produce a large number of variants, generating FNs 
with different cell-adhesive and ligand-binding properties, which allows cells to precisely alter the 
composition of the ECM in a developmental and tissue-specific manner 48. Figure 2.8 provides an overview 
of the different FN variants, their integrin and ligand binding sites, their major proteolytic digestion sites 
and sites involved in fibronectin fibrillogenesis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Overview of the structure and different splice variants of FN (adapted from 48)  
Overview of the domain structure of plasma, cellular and single chain FN. Integrin and ligand (collagen, 
heparin etc.) interactions sites are marked in yellow or purple respectively. Red arrows indicate sites 
accessible for proteolytic cleavage by a variety of extracellular proteinases. All domains involved in 
fibronectin self-assembly and fibrillogenesis are marked in blue.  
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2.4 Fibronectin Fibrillogenesis  
 
FN fibrillogenesis and matrix assembly is a complex process involving binding domains and repeating 
modules from all regions of FN. FN fibrillogenesis requires the interaction of FN molecules with cell surface 
integrins as well as with other FN molecules 54. Upon secretion FN dimers bind to transmembrane integrin 
receptors. The primary receptor mediating FN assembly is integrin α5β1 58, although other integrins can 
have a similar function under appropriate circumstances 59. Integrins link FN to the actin cytoskeleton 
through interactions between their cytoplasmic domains and cytoskeletal-associated proteins, such as 
focal adhesion kinase (FAK),  talin and vinculin 60. The association of cytoplasmic domains of integrins with 
the actin cytoskeletal network is essential for FN matrix assembly. FN-integrin interactions activate the 
RhoA GTPase pathway followed by RhoA-Rock mediated actin–myosin interactions which leads to the 
contractility of the cytoskeleton, resulting in FN fibril formation (Fig. 2.9) 51, 61, 62. Treatments that enhance 
contractility stimulate matrix assembly whereas inhibition of myosin light chain kinase or RhoA GTPase 
reduces assembly 61, 63. This linkage is not only important for FN fibrillogeneses, but also allows the ECM 
to influence cell signaling via mechanotransduction. The actin-talin-integrin-FN clutch is transmitting 
mechanical forces caused by tissue rigidity into biochemical signals. Strong FN accumulation and increased 
tissue stiffness, lead to conformational changes in talin, which influences the organization of the actin 
cytoskeleton, followed by the translocation of the transcription factor YAP into the nucleus (Fig. 2.9) 64.  
On the outside of the cell, interactions between FN and integrins promote FN–FN association and fibril 
formation, most likely by inducing conformational changes in bound FN. During the assembly process FN- 
fibrils are converted into a detergent deoxycholate (DOC)-insoluble fibrillar network 54, 65. The thickness 
of FN fibrils varies substantially from 10 to 1000 nm in diameter indicating that fibrils probably range from 
a few to several hundred FN molecules across 54, 66.  
A major site for FN self-association is within the N-terminal assembly domain spanning the first five type 
I repeats (I1-5) (Fig. 2.8) 67-69. The N-terminal domain has several other binding partners in addition to FN 
such as fibrin, heparin, thrombospondin-1, and tenascin-C 51, 70 and is therefore a key mediator for proper 
FN fibrillognesis and ECM maturation. Recombinant FN lacking the first five type I repeats is unable to 
assemble into fibrils, while addition of recombinant N-terminal 70 kDa FN fragment containing the first 
five type I repeats blocks FN matrix assembly 67, 68. In addition to these non-covalent interactions involving 
the N-terminal FN domains, dimerization of FN also depends on covalent associations within the C-
terminal disulfide bonds. Indeed monomeric FN lacking the C-terminal region is not able to assemble into 
fibrils 68, 71.  
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Figure 2.9: Integrin signaling mediates FN assembly and activation of YAP 
A. FN assembly requires focal adhesion kinase (FAK) activation and RHOA–ROCK-mediated actomyosin 
contraction 62 B. Integrin receptors bind to FN. The mechanical stimulus leads to conformational changes 
in talin which triggers the activation of YAP via FAK-Src signaling in a PI3K–PDK1-dependent manner 72.  
 
Although the N-terminal repeats I1-5 are the most important ones for fibronectin fibril assembly, other FN 
domains participate and regulate FN-FN interactions, fibril assembly and the formation of a DOC insoluble 
matrix as well. Deletion of the entire III1–2 domain for example, significantly reduces matrix assembly. This 
small domain contains at least two FN binding sites and binds in addition to various proteoglycans. Where 
deletions of the FN domain III1 alone had no significant influence on FN fibril assembly, deletion of the 
domains III1-2 significantly reduced ECM assembly with a primary effect on the ECM maturation into a DOC-
insoluble matrix 73. This observation indicates that, other than the N-terminal assembly domain (I1-5) which 
is an important mediator for the initiation of FN assembly and fibrillognesis, the FN binding site in III2 or 
III1–2 together mainly participate in the maturation of the FN matrix rather than in in the initiation of FN 
fibrillogenesis. 
FN–FN interactions are not only important for fibril formation but they can also participate in 
intramolecular interactions that keep soluble FN in a compact form, unable to form fibrils in solution. FN 
fragments containing the domains III2–3 and/or III12–14 were shown to inhibit FN assembly, possibly through 
dual blockade of FN–FN and FN–cell interactions 74, 75.  
A B 
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As mentioned above, FN fibril assembly starts with the binding of FN to cell surface integrins. This step is 
required for subsequent FN-FN interactions, fibril maturation and the formation of multimeric structures 
54. Incorporation of FN requires interactions with integrins 58, but FN is also recruited from solution into 
existing fibrils through homophilic interactions that are independent of the RGD integrin binding site 76. 
FN in solution has a very compact globular structure, where many binding sites required for assembly are 
not properly accessible. FN is transformed from a compact conformation to an extended conformation as 
it goes from solution to fibrils. Thus the extension of FN and the exposure of FN binding sites play 
important roles in the initiation of FN fibrillogenesis. Such conformational changes are also dependent on 
the actin cytoskeleton. Stress fibers, which are contractile actin-myosin filaments, generate tension at 
sites of contact between integrins and FN. Integrin engagement with the cytoskeleton allows these 
receptors to translocate away from the contact sites along actin filaments and, in the process, to pull on 
bound FN molecules, which leads to the extension of the FN molecule needed for FN-FN interactions and 
fibrillogenesis 77 61. FN–FN interactions, where FN dimers associate end-to-end 78, initially give rise to short 
fibrils around the cell periphery. As assembly proceeds, longer and thicker fibrils are formed. As the fibrils 
grow, they are converted from a detergent DOC-soluble form into DOC-insoluble material, a process that 
is irreversible 65. The exact mechanism by which FN fibrils become DOC-insoluble is not well understood. 
However, fibril insolubility appears to depend on strong noncovalent, protein–protein interactions  79. 
Extension of FN during assembly requires disruption of interdomain interactions. It could be shown that 
partial unfolding of the β-sheet structure of the III9 module promoted self-polymerization through β-
strand exchange 80. Domain swapping and the formation of intermolecular β-sheets might be the primary 
mechanism that underlies DOC-insolubility 81. Figure 2.10 provides an overview of FN assembly and 
fibrillogenesis.  
The FN matrix is not a static structure. Fibrils within a matrix are under significant tension and relax to as 
little as one-quarter of their original length when tension is removed, for example, when one end of a 
fibril is released from its attachment site. Thus, cell contractility and tension are needed to initiate 
fibrillogenesis and to maintain fibril architecture in established matrices 82.  
Proper FN matrix assembly is an important step for the development of an intact mature ECM. Remodeling 
of the FN network can have severe effects on the overall composition of the ECM and influence processes 
such as cell signaling, adhesion and proliferation. How ECM is assembled at cell and tissue surfaces has 
become an important question, because of the growing realization that the three-dimensional (3D) 
organization of the ECM can have distinct instructive properties in terms of cellular responses. FN, along 
with other ECM glycoproteins, collagens, and proteoglycans, are assembled into complex 3D 
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microenvironments that provide structural support to cells and tissues, and restrict the diffusion of growth 
factors and other soluble signaling molecules to direct or influence cell behavior, proliferation and growth, 
gene expression, and cell fate specification 3. Therefore FN network formation has a crucial role during 
organ development. For example, FN is an important regulator of cleft formation during epithelial 
branching morphogenesis. Inhibition of FN assembly or knock-down of FN1 blocks cleft formation and 
branching, whereas the addition of exogenous FN promotes these processes. Interestingly, the assembly 
of FN at sites of cleft formation was associated with a reduction in cadherin-dependent cell–cell 
adhesions, suggesting a possible mechanistic link or adhesive “crosstalk” critical for branching 
morphogenesis. Btbd7 was recently discovered as one of the key players during FN induced cleft 
formation. It is expressed by cells in the emerging clefts in response to local FN accumulation. Btbd7 
induces Snail2 and suppresses E-cadherin expression thereby promoting morphogenetic changes required 
for cleft formation (Fig. 2.11) 83, 84.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Major steps of FN fibril assembly 
A. Electron microscopy image of a FN dimer. The red arrows indicate the C-terminal disulfide bonds 8. B. 
(1) Compact soluble FN binds to integrin α5β1 (gold) via its cell binding domain (blue). The exact 
organization of FN subunits in the compact form of soluble FN is not known but appears to depend on 
intramolecular interactions between III2–3 and III12–14 and other FN binding sites (red modules). (2) FN 
binding to integrins and other receptors (pink bars) induces reorganization of the actin cytoskeleton 
(green lines) and activates intracellular signaling complexes (silver circles). Cell contractility aids in FN 
conformational changes thus exposing sequestered FN binding domains in the extended molecule. (3) 
Fibrils form through FN–FN interactions. Alignment of FN molecules within fibrils might vary depending 
on which domains interact, such as I1–5 binding to III1–2 versus with III12–14 54. C. FN matrix of wild type 
mouse embryonal fibroblasts (MEF) after 3 days in culture 85.    
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Figure 2.11: ECM remodeling during cleft formation and branching morphogenesis (adapted from 62) 
Cleft formation and deepening during branching morphogenesis. Fibronectin is locally assembled in the 
basement membrane and induces BTBD7 at the base of forming clefts. BTBD7 expression leads to the 
upregulation of the transcription factor SNAIL2 and the downregulation of the adhesion molecule 
E-cadherin. These molecular events promote alterations in cell shape, decrease cell–cell adhesion and 
promote a motile phenotype. 
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2.5 Extracellular Metalloproteinases and their function in ECM degradation and remodeling  
 
2.5.1 The MMP-family  
 
A number of extracellular proteinases, which are classified as either exopeptidases or endopeptidases 
based on whether they cleave terminal or internal peptide bonds, respectively, are involved in the 
degradation and remodeling of the ECM. Most endopeptidases are classified as serine, cysteine, aspartic 
or metalloproteinases based on their catalytic mechanism and inhibitor sensitivities. Based on sequence 
considerations, metalloproteinases are further separated into five superfamilies. The MMP-, ADAMTS- 
and the ADAM-family are all part of the metzincin superfamily. The metzincin superfamily is distinguished 
by a highly conserved motif containing three histidine residues that bind zinc at the catalytic site and a 
conserved methionine turn located beneath the active site zinc 86. The most prominent family within the 
metzincin superfamily is the Matrix Metalloproteinase (MMP) family. MMPs are endopeptidases that are 
either fully secreted or membrane bound (MT-MMP). MMPs show a broad spectrum of substrates within 
the ECM and are grouped into eight distinct structural classes (Fig. 2.12) 87. Many of the extracellular 
signaling events that regulate cell behavior happen in close proximity of the cell membrane and are 
regulated by pericellular proteolysis 87. Therefore close proximity of MMPs to the cell membrane is needed 
to achieve a proper cell response upon ECM proteolysis. Whereas the MT-MMPs are covalently linked to 
the cell membrane, secreted MMPs either localize to the cell surface by binding to cell surface receptors 
such as integrins 88 and CD44 89, 90 or through interactions with cell-surface-associated heparan sulphate 
proteoglycans, collagen type IV and extracellular matrix metalloproteinase inducer (EMMPRIN) 91.  
MMPs are secreted as inactive zymogens (pro-MMPs). Interactions of the propeptide with the catalytic 
domain keep the enzyme in its inactive state. To activate pro-MMPs the proteolytic removal of the 
propeptide is required 92. Most MMPs are activated outside of the cell by other MMPs or serine 
proteinases. However MT-MMPs, MMP11 and MMP28 can also be activated within the secretory pathway 
by the proprotein convertase furin 93, 94. MMP activity is tightly controlled by endogenous inhibitors. The 
best studied inhibitors of MMPs are TIMPs (Tissue Inhibitors of Metalloproteinases). The TIMPs represent 
a family of at least four secreted proteins (TIMPs 1–4) that reversibly inhibit MMPs. Individual TIMPs differ 
in their ability to inhibit various MMPs 91. The inhibitory effect of TIMPs is not just restricted to MMPs. 
TIMP3 was shown to inhibit ADAMs-10 and -17, ADAMTS4, and ADAMTS5 95, where TIMP1 can inhibit 
ADAMTS-1 91, 96. TIMPs are not the only endogenous MMP inhibitors. Indeed, α2-macroglobulin is a major 
endogenous inhibitor of MMPs, but also inhibits a broad variety of other proteinases such as ADAMs and  
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Figure 2.12: Overview of the eight structural classes of MMPs (adapted from 87) 
Matrix metalloproteinases (MMPs) can be divided into eight distinct structural groups, five of which are 
secreted and three of which are membrane-type MMPs (MT-MMPs). All secreted MMPs share the same 
N-terminal structural organization. Every secreted MMP has an amino-terminal signal sequence (Pre), a 
propeptide (Pro) containing a zinc-interacting thiol (SH) group, which maintains them as inactive 
zymogens, and a catalytic domain with a zinc-binding site (Zn). Whereas the minimal-domain MMPs are 
comprised of these domains, other secreted MMPs contain an additional hemopexin domain at their C-
terminus. The gelatin-binding MMPs contain additional inserts that resemble collagen-binding type II 
repeats of fibronectin (Fi), where the furin-activated secreted MMPs contain a recognition motif for the 
proprotein convertase furin (Fu) that allows intracellular removal of the propetide. This motif is also found 
in the vitronectin-like insert (Vn) MMPs and the membrane-type MMPs (MT-MMPs). MT-MMPs include 
transmembrane MMPs that have a C-terminal, single-span transmembrane domain (TM) and a very short 
cytoplasmic domain (Cy). Some MMPs contain a glycosylphosphatidylinositol (GPI)-anchor. MMP-23 is 
characterized by its unique cysteine array (CA) and immunoglobulin (Ig)-like domains. It has an N-terminal 
signal anchor (SA) that targets it to the cell membrane, which makes it the only type II transmembrane 
MMP. 
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ADAMTSs. Inhibition of MMPs by α2-macroglobulin is an irreversible process. α2-macroglobulin contains 
a 35 amino acid "bait" region, which is especially susceptible to proteolytic cleavage. MMP binding and 
cleavage of α2-macroglobulin, leads to conformational change within α2-macroglobulin such that the α2-
macroglobulin collapses about the proteinase. In the resulting α2-macroglobulin-MMP complex, the 
active site of the proteinase is sterically shielded, thus substantially decreasing access to protein 
substrates 97. The α2-macroglobulin-MMP complexes are further removed by scavenger receptor-
mediated endocytosis. Therefore α2-macroglobulin plays an important role in the irreversible clearance 
of MMPs 98. Because α2-macroglobulin is an abundant plasma protein, it represents the major inhibitor 
of MMPs in tissue fluids, whereas TIMPs may act locally 91.  
MMPs have a broad variety of substrates within the ECM, such as collagens, fibronectin and laminin 99-101. 
Cleavage of the ECM components by MMPs not only facilitates cell migration, but also leads to the release 
of biologically active ECM cleavage products. Cleavage of plasminogen and Col-XVIII, for example, results 
in the generation of the anti-angiogenic factors angiostatin and endostatin 102, 103. Moreover, ECM 
degradation by MMPs leads to the release of bound growth factors, such as insulin-like growth factors 
(IGFs) and fibroblast growth factors (FGFs) and therefore directly affects cell signaling 104, 105. In addition 
to causing the activation and release of cytokines and growth factors, MMPs can also cleave their cell 
surface receptors. MMP2, for example, cleaves FGF receptor 1 at a specific extracellular juxtamembrane 
site, thereby releasing a soluble receptor fragment that retains its ability to bind FGF.  Soluble FGF receptor 
type 1 has been found in the circulation and in vascular basement membranes and may indirectly 
influence FGF availability 106. Moreover MMP9 was shown to cleave interleukin 2 receptor α (IL2Rα) on T 
cells and therefore significantly downregulate their proliferative response to interleukin 2 (IL2) 107. The 
substrate specificity of MMPs is not just limited to secreted ECM molecules and receptors. MMPs also 
preoteolyticaly act on cell-adhesion molecules such as E-cadherin and CD44 108, 109. Proteolytic processing 
of those molecules strongly increases cell invasion. Further leads the processing of αv integrin precursor 
by MMP14 to an increase in cancer cell invasion 110. Finally as already mentioned above MMPs can activate 
their own zymogens 24.  Figure 2.13 summarizes the different pathways and molecules that MMPs act on.    
MMPs are involved in all processes that require ECM remodeling. Changes in expression levels of MMPs 
can therefore have severe consequences during organ development and play a significant role in the 
development of diseases, such as osteoarthritis or inflammatory processes. However, the biggest interest 
has been in the contribution of MMPs to cancer progression and metastasis. Because of their strong 
contribution to tumor growth and metastasis MMPs have been intensively studied over the last decade 
111, 112. MMPs are generally present in greater amounts and activated more often in and around malignant 
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cancers, with the highest expression taking place in areas of active invasion at the tumor-stroma interface 
91.  Significant positive correlations have been found between the expression of multiple MMPs and 
various indicators of a poor prognosis in virtually all types of cancer. In some instances, increased MMP 
levels represent an independent predictor of shortened disease-free and overall survival 87, 91.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: Overview of MMP-induced cellular processes and substrate specificity (adapted from 113).  
(1) Breakdown of ECM is a prerequisite of cell migration and invasion during tumor metastasis as well as 
in developmental processes. (2) Proteolytic products of ECM, such as angiostatin, endostatin and 
neostatin, exhibit potent antiangiogenic properties. However, MMPs can also release proangiogenic 
factors, such as fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), from their 
bound, inactive form, thus contributing to angiogenesis. (3) MMPs can activate other MMPs from their 
pro-enzyme forms by removing their prodomain. (4) MMPs can also process various non-bound proteins. 
For example MMP-mediated inactivation of IGFBPs leads to enhanced IGF activity. (5) MMPs also induce 
proteolytic shedding of extracellular domains of transmembrane and surface-bound proteins, such as 
RANKL, E-cadherin, TNF and Fas, enhancing tumor-induced osteolysis and epithelial-to-mesenchymal 
transition, as well as apoptosis of tumor cells when releasing TNF-α.  
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In epithelial cancers, however, most of the upregulated MMPs are expressed by the supporting stromal 
cells rather than by the carcinoma cells themselves 114. Without the aid of ECM-degrading MMPs, 
endothelial cells would be unable to penetrate the ECM, and cancer cells would be incapable to cross the 
matrix barriers that otherwise contain their spread. However, recent data indicate that MMPs do far more 
to influence cancer progression and metastasis, than solely remove the physical barriers. MMP3 for 
example can promote late epithelial-to-mesenchymal phenotypic changes, via E-cadherin degradation 
amongst other things, what leads to a more aggressive malignant behavior 115. Conversely, some MMPs 
appear to inhibit cancer progression 91. Similar to ADAMs (discussed in the next chapter), GPI-linked MT4-
MMP can cleave membrane-bound pro-TNF-α to generate active soluble TNF-α, therefore releasing a pro- 
apoptotic molecule, which acts negatively on tumor cell growth and proliferation  91, 116.  
 
 
2.5.2 The ADAMs-family 
 
Another important family within the metzincin superfamily are adamalysins. Adamalysins are further 
divided into the ADAMs-family, the ADAMTS-family (discussed in the next chapter) and the snake venom 
matrix proteinases (SVMP) 91. The three subfamilies share similar N-terminal domain structure, but differ 
in their C-terminal domains. All of them consist of a prodomain, a metalloprotease domain, a disintegrin 
domain and a cysteine-rich domain. ADAMs (A Disintegrin and Metalloproteinase) have in addition an 
EGF-like domain, a transmembrane domain, and a cytoplasmic tail (Fig.2.14). At least 40 ADAMs have 
been described, 25 of which are expressed in humans. Among those, 19 display proteolytic activity. 
ADAMs are transmembrane proteins, what distinguishes the ADAMs family from the ADAMTSs, which are 
all fully secreted proteinases 117.  
The expression pattern of different ADAMs varies considerably. In mammals, many of them (including 
ADAMs 2, 7, 18, 20, 21, 29, and 30) are exclusively or predominantly expressed in the testis and/or 
associated structures. Other members (ADAMs 8, 9, 10, 11, 12, 15, 17, 19, 22, 23, 28, and 33) show a 
broader distribution pattern 117.   
Although ADAMs are kept in an inactive state via their prodomain, similar to MMPs, they are mostly 
activated by furin and other proprotein convertases (PC) and not by other family members. Indeed, 
ADAMs have not been shown to activate each other, as it is observed for members of the MMP family 118. 
However some ADAMs, mainly ADAM8 and ADAM28, were shown to undergo autocatalytic activation 119, 
120. The prodomain not only keeps the proteinase inactive, but acts in addition as an internal chaperone 
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supporting the proper folding of a mature ADAM protein 121. Only human ADAM15 contains an RGD motif 
within its disintegrin domain and is therefore able to associate with αvβ3 and α5β1 in an RGD-dependent 
manner 122. However, although missing the RGD motif, some members of the ADAM family are still 
capable of interacting with certain integrin receptors such as integrin α4 and α9, via binding by aspartic 
acid-containing sequences 123. The cytoplasmic domain varies considerably in length and sequence 
between the different members of the ADAMs family. However, the most common motifs within the 
cytoplasmic domains are binding sites for SH3 domain containing proteins. Several ADAMs also have 
potential phosphorylation sites for serine-threonine and/or tyrosine kinases 124. Via their C-terminal 
cytoplasmic domain ADAMs have a direct role in cell signaling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14: Overview of the domain organization and function of ADAM metalloproteinases (adapted 
from 125) 
ADAMs are composed of distinct domains providing the proteins with multiple functions. All ADAM 
proteins contain a prodomain (Pro) keeping the proteinase in an inactive state. In the case of ADAM15 
the disintegrin domain contains the integrin binding motif RGD, allowing integrin receptor binding. Most 
ADAMs contain a transmembrane domain after the EGF-like domain which anchors them in the cell 
membrane. The cytoplasmic domains bind to proteins of the cytoskeleton and serves as phosphorylation 
site of several kinases, therefore participating directly in cell signaling. Via binding and shedding of cell 
surface receptors and receptor ligands, ADAMs influence cell signaling, adhesion and proliferation.  
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ADAMs have gained great interest, because of their function in protein ectodomain shedding. In this 
regard ADAM17, also known as TNF-α converting enzyme (TACE), is the most studied member of the 
ADAMs family. ADAM17 activates the membrane bound precursor form of TNF-α via its release form the 
cell surface 117, 126. Moreover ADAM17 not only activates TNF-α, but is also involved in cytokine receptor 
shedding mainly in activating the TNF-α receptor and therefore regulating TNF-α signaling in two different 
ways 127. Over the years especially ADAM17 has emerged as a major sheddase with an extremely broad 
substrate range. ADAMs are not just involved in the shedding of cytokines and cytokine receptors, but 
also have been linked to growth factor, mainly EGFR ligand, shedding. ADAMs have been linked to the 
shedding of at least 6 EGFR ligands (TNF-α, EGF, HB-EGF, betacellulin, epiregulin and amphiregulin) 128 and 
play an important role in paracrine, autocrine and juxtacrine signaling (Fig. 2.15) 129. Although the major 
interest in ADAMs is due to their sheddase function, they also cleave the amyloid precursor protein 130, 
cell adhesion molecules such as E-cadherin 131 and process a variety of ECM proteins, mainly within the 
basement membrane, such as type IV collagen and fibronectin 132, 133.  
As previously mentioned, many of the ADAM family members are exclusively expressed in gonad cells 
where they play an important role regulating fertilization by promoting the fusion of egg and sperm cells. 
In humans the adhesion of sperm and egg requires the disintegrin domain of ADAM2 134. Mutations within 
this domain strongly inhibit egg binding 135. However, ADAMs are not just important regulators of 
fertilization, but have been implicated in a variety of human diseases such as Alzheimer’s disease. 
Alzheimer’s disease is caused by the accumulation of β-amyloid peptides. The β-amyloid peptides are 
formed by stepwise processing of the amyloid precursor protein (APP) by β and γ-secretases. An 
alternative pathway of APP secretion is through the action of α-secretase activity. The soluble APPα 
(sAPPα) that results from α-secretase activity has positive neurotrophic effects, and opposes the harmful 
effects of β-amyloid formation 117. ADAM9, 10 and 17 have been shown to cleave the amyloid precursor 
generating the soluble APPα protein 130, 136, 137. It is therefore assumed that ADAMs act in a protective way 
preventing the development of Alzheimer’s disease.  
Due to their sheddase activity towards EFGR ligands and cytokines, ADAMs also regulate cellular processes 
such as cell proliferation, adhesion and migration (Fig. 2.13). It is therefore not surprising that a variety of 
members of the ADAM family have been linked to tumor development. ADAM9 and 15 are strongly 
overexpressed in pancreatic tumors 138 where ADAM28 was shown to be overexpressed in breast 
carcinomas 139.    
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Figure 2.15: Schematic representation of ectodomain shedding and cell signaling by ADAM proteinases 
(adapted from 129)  
A. A schematic representation of an ADAM protein that is engaged in membrane-proximal cleavage of a 
membrane protein, which results in the release of its soluble ectodomain. Diverse structural and 
functional molecules are subjected to ectodomain shedding, such as TNFα, HB-EGF and other molecules. 
B. A receptor–ligand pair is used to illustrate possible roles of ectodomain shedding. In the absence of 
shedding, a membrane-anchored ligand might only engage its receptor in a juxtacrine or autocrine 
fashion. Receptors might also be shed, which could result in their activation or inactivation.  
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2.6 The ADAMTS superfamily 
 
2.6.1 Structure and Proteolytic Mechanisms  
 
The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family is part of the 
metzincin superfamily. The ADAMTS family is closely related to the ADAM family with regard to their N-
terminal domain structure, but lacks the C-terminal transmembrane domain and is therefore fully 
secreted. Instead ADAMTSs contain at least one thrombospondin (TSR1) domain (Fig. 2.16). The human 
ADAMTS superfamily includes 19 ADAMTS members and 7 ADAMTS-like (ADAMTSL) proteins. The 19 
ADAMTS family members can be further sub-grouped on the basis of their known substrates, namely the 
aggrecanases or proteoglycanases (ADAMTS1, 4, 5, 8, 9, 15 and 20), the procollagen N-propeptidases 
(ADAMTS2, 3 and 14), the cartilage oligomeric matrix protein-cleaving enzymes (ADAMTS7 and 12), the 
von Willebrand Factor proteinase (ADAMTS13) and a group of orphan enzymes (ADAMTS6, 10, 16, 17, 18 
and 19) 140. To date, all known substrates are either ECM proteins and many members of the ADAMTSs 
family have at least one known substrate, although it is likely that other substrates are yet to be 
discovered 141. All ADAMTSs share a common domain organization comprising a signal peptide, a 
prodomain, a catalytic domain, a disintegrin-like domain, a central TSR1 repeat, a cysteine-rich and a 
spacer domain. With the exception of ADAMTS4, all other ADAMTS enzymes have further TSR1 repeats 
and several family members have additional, unique modules (mucin-like domains, Gon-1 domains, 
protease and lacunin (PLAC) domain and CUB-domains) at their C-terminus 141. The entire C-terminal 
region downstream of the central TSR1 is termed the ancillary domain, and this is where the greatest 
differences between ADAMTS family members occur (Fig. 2.16) 140.   
Similar to ADAM family members, ADAMTSs contain a prodomain that keeps the proteinase in its inactive 
state and acts additionally as an internal chaperone mediating proper folding. Activation of the zymogen 
into a fully active proteinase requires catalytic processing and release of the prodomain from the catalytic 
center. It is, however, unlikely and could not be shown so far that ADAMTSs activate each other, as is the 
case for certain members of the MMP family. Moreover all ADAMTS family members contain a consensus 
sequence making the protease susceptible for activation by proprotein convertases such as furin. Furin 
activation can occur within the trans-Golgi network as well as extracellularly in close proximity to the cell 
surface 142, 143. However, not all members of the ADAMTS family need the removal of the prodomain to be 
activated. ADAMTS13, for example, does not require cleavage of the prodomain to be fully active 144.  
Additionally it could be shown that ADAMTS9 loses its activity towards its substrate versican upon removal 
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A B 
of the prodomain 145. The catalytic domain of the ADAMTS family members has the highest degree of 
sequence homology. ADAMTS enzymes have in common with other members of the metzincin 
superfamily, the active-site consensus sequence HEBxHxBGBxH, in which the three histidine residues 
coordinate a zinc ion essential for hydrolysis, and where B represents bulky apolar residues (Fig. 2.16). C-
terminal to the third histidine is a highly conserved methionine that constitutes the ‘Met-turn’, a tight 
turn common to the catalytic domain and the reason for the metzincin nomenclature 146.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16: Overview of the domain organization and the catalytic center of ADAMTS   
A. Structure of ADAM and ADAMTS proteinases. Both proteinase families share common domain 
structures such as a prodomain (Pro) with a furin cleavage site (FU) for activation, a metalloproteinase 
domain with a zinc ion bound to the catalytic center, a disintegrin domain (Dis) and a cysteine rich domain. 
Unlike ADAMs, ADAMTSs contain neither a transmembrane domain (TM), nor a cytoplasmic domain. 
ADAMTSs contain a first thrombospondin type 1 motif (TSR1) after the Dis domain and a variable amount 
of TSR1 motifs in their C-terminus. Most ADAMTSs contain an additional domain (R), such as mucine, CUB 
or PLAC domains at their C-terminus after the last TSR1 motif. Unlike ADAMs, ADAMTSs are fully secreted.  
Figure adapted from 125  B. Cartoon representation of the active site of ADAMTS13. The three histidine 
(His) residues coordinating the zinc ion (Zn2+) are marked in red. The catalytic Glu225 (purple) polarizes a 
water molecule that is stabilized by the coordinated Zn2+ ion, and is part of the proteolytic machinery. 
Figure adapted from 147.  
 
Unlike ADAMs none of the ADAMTSs have been reported to interact with integrin receptors via their 
disintegrin-like domain 140. Crystal structure data for ADAMTS1, 4 and 5 reveal that the disintegrin-like 
domain is a cysteine-rich region that stacks against the metalloproteinase active-site cleft, implying that 
it functions to regulate activity, perhaps by providing an auxiliary substrate-binding surface 148, 149.  
While the catalytic domain is strongly conserved among different ADAMTSs, they show less structural 
homology within their C-terminal ancillary domains. The ancillary domains are responsible for the 
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association with the ECM, regulation of protease activity, and for specification of substrate-binding 
preferences. All ADAMTSs contain a TSR1 module after the disintegrin-like domain, a cysteine-rich domain 
and a spacer domain within their ancillary domains 140. The cysteine-rich and spacer domains of ADAMTS1, 
4, and 5, for example, determine binding to sulphated glycosaminoglycans and tissue localization 150, 151. 
With the sole exception of ADAMTS4, the spacer domain is followed by 1 to 14 further TSR1 modules and 
additional motifs that are characteristic of particular subgroups. The ADAMTS9/20 pair has the largest 
number of TSRs and each concludes with a GON-1 module (first described in C. elegans Gon-1) 152. 
ADAMTS13 is unique in having two CUB modules. Several ADAMTSs (ADAMTS2, 3, 6, 7, 10, 12, 14, 16, 17, 
18 and 19) possess a PLAC domain. In ADAMTS7 and 12, a mucin/proteoglycan domain is interposed in 
the middle of the seven C-terminal TSR1s (Fig. 2.17). The sequence of the C-terminal TSR1 modules is 
more variable than the central thrombospondin module, but their function appears to be ECM binding as 
well. The ancillary domains of ADAMTSs can be proteolytically processed, affecting secretion, localization, 
activation and catalytic functions 140, 153, 154.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17: Overview of the ADAMTS family (adapted from 141) 
The domain structure and phylogenetic analysis of the ADAMTS family. Domains are not to scale. 
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Like MMPs and ADAMs, ADAMTSs show restricted susceptibility to inhibition by TIMPs, where TIMP3 
emerges as the most effective inhibitor 155. The activity of the ADAMTSs is also controlled by their 
internalization and degradation. ADAMTS4 and 5, for example, have been shown to be internalized upon 
binding to LRP-1 156, 157.  
 
 
2.6.2 ADAMTSs in Development and Disease 
 
ADAMTSs are not as well characterized with regard to their substrate specificity and mechanisms of 
action, compared to MMPs and ADAMs. The known substrates of ADAMTSs are mainly ECM proteins and 
little is known about their potential contribution to cell signaling and how they influence cellular 
responses and cell behavior upon ECM protein cleavage. However, improving technologies and growing 
research in the field is revealing an increasing number of substrates and leading to a better understanding 
of the underlying mechanisms of ADAMTS-mediated substrate processing.  
The ADAMTS proteinases have important roles in tissue development and maintenance, and their 
dysregulation or mutation is associated with a number of diseases. ADAMTS2, ADAMTS3 and ADAMTS14 
are procollagen N-proteinases 158-160 and loss-of-function mutations in ADAMTS2 cause Ehlers–Danlos 
syndrome type VIIC, a connective tissue disorder characterized by severe skin fragility 161. The best 
characterized members and most intensively studied ones however are ADAMTS1, 4, 5 and 13.  
The proteoglycan aggrecan is a major constituent of the chondrocyte ECM and excessive degradation can 
have severe physiological consequences, such as osteoarthritis (OA). Aggrecan is one of the first matrix 
components to undergo measurable loss that ultimately leads to a loss of cartilage function and OA. 
Therefore, aggrecan degradation is considered to be a crucial initial event in the development of OA, 
which is followed by essentially irreversible collagen degradation 162. Various studies indicate that 
ADAMTS4 and 5 are the two major aggrecanases in cartilage 163, 164. A tight regulation of ADAMTS4 and 5 
activity is crucial for maintaining a fine balance between aggrecan anabolism and catabolism. In diseases 
such as OA the regulation of aggrecanase activity is disturbed in favor of catabolism 162-164. The most 
significant aggrecan cleavage site for ADAMTS4 and 5 in OA pathogenesis is located at a highly conserved 
sequence TEGE373↓374ARGS. Antibodies that recognize the 374ARGS neo-epitope 165 are important tools 
for tracking protease activity, OA progression and led to the original discovery of ADAMTS4 and 5 96, 166.  
Particularly ADAMTS5 has been shown to be the major aggrecanase. In vitro it has been shown to be about 
1,000 times more potent than ADAMTS4 167. Therefore ADAMTS5 has emerged as one of the main targets 
in the treatment of OA and several attempts have been undertaken to generate specific ADAMTS5 
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inhibitors. Two recent publications demonstrated the efficacy of ADAMTS5 inhibition in vivo using 
monoclonal antibodies. The antibody GSK2394002 developed by researchers at GlaxoSmithKline was 
shown to protect the cartilage matrix from degradation in both mice and cynomolgus monkeys. 
Additionally it could reduce pain-associated allodynia in mice 168. Another promising antibody against 
ADAMTS5 is CRB0017, a recombinant monoclonal antibody of high affinity and selectivity against the 
spacer domain of ADAMTS5. Intra-articular injection of CRB0017 in STR/ort male mice, which 
spontaneously develop OA, resulted in significant chondroprotection 169.     
Other ADAMTSs may be physiologically relevant aggrecanases in tissues other than cartilage. ADAMTS1 
for example, was shown to be relevant in aggrecan processing during kidney development 170. Cofactors 
as well as C-terminal processing may play a functional role in mediating accreganase activity in addition 
to tissue specific expression. Local cofactors such as fibulin-1 for example, which binds to ADAMTS1 and 
increases its aggrecanase activity, may be important in determining which enzyme has the principal 
activity in a particular tissue context 170. Additionally it could be shown that MMP17-mediated ancillary 
domain cleavage of ADAMTS4 enhances its ability to cleave aggrecan 171. 
Another disease linked to ADAMTSs is thrombotic thrombocytopenic purpura (TTP). TTP is a rare disorder 
of the blood-coagulation system, causing extensive microscopic clots to form. If untreated the disease 
leads to the development of severe hemolytic anemia, abundant schistocytes, profound 
thrombocytopenia, neurological deficits, renal injury, fever and death within the first months of illness 172. 
A breakthrough in understanding the pathogenesis of TTP came with the discovery of ADAMTS13 and its 
main substrate the von Willebrand factor (vWF) 173.  The vWF interacts with blood platelets and thereby 
promotes blood clotting. However, in the absence of proteolytic cleavage there is an accumulation of 
unusually large vWF multimers, which triggers intravascular platelet aggregations and microthrombosis 
174. VWF is secreted from endothelial cells as ultra large multimers, and ADAMTS13 progressively reduces 
the size of those vWF multimers as they circulate in the blood. Under low-shear conditions, vWF 
multimers adopt a loosely coiled, condensed shape. Above a critical shear rate, vWF multimers extend 
and unfold the A2 domain exposing a cryptic Tyr-Met bond which is cleaved by ADAMTS13 175, 176. Under 
normal conditions vWF multimers bind platelets on the endothelial cell surface or at sites of vascular 
injuries. Compared to soluble vWF, bound vWF requires much lower shear stress to induce conformational 
changes that promote binding to platelets or cleavage by ADAMTS13 177. Cleavage of vWF by ADAMTS13 
than leads to the release of smaller vWF multimers together with any attached platelets. The proteolytic 
cleavage of vWF therefore prevents the formation of microvascular thrombosis, tissue ischemia and 
infarction 172. ADAMTS13 deficiency can cause the cardinal features of TTP, thrombocytopenia and 
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microangiopathic hemolytic anemia, by failing to regulate VWF-dependent platelet adhesion (Fig. 2.18). 
In most cases ADAMTS13 deficiency leading to the development of TTP is caused via autoantibodies to 
ADAMTS13 (also known as acquired TTP). These anti-ADAMTS13 antibodies usually block the proteolytic 
activity of ADAMTS13 towards vWF 178. Another rarer mechanism for ADAMTS13 deficiency is due to loss-
of-function mutations within the ADAMTS13 gene (inherited TTP) 173, 179.  
The knowledge whether the patient is suffering from inherited TTP or acquired TTP, is crucial for an 
effective treatment. In case of inherited TTP, plasma infusions are the most effective way of treatment 
although connected to a variety of side effects such as severe allergic reactions. Plasma exchange remains 
the standard therapy for acquired TTP. However, rituximab an antibody that binds and kills all B-cells 
including the ADAMTS13 autoantibody producing ones, shows to be beneficial in most patients when used 
in combination with plasma exchange 172.  
 
 
 
 
 
 
 
 
 
 
 
 
 
So far ADAMTS13 remains unique in its ability to cleave the soluble plasma protein vWF. However, the C-
terminal domain of ADAMTS18 has recently been shown to interact with blood platelets via binding to 
platelet integrin GPIIIa. Upon secretion of ADAMTS18 by endothelial cells the C-terminus is cleaved by 
thrombin and interacts with GPIIIa, leading to oxidative platelet fragmentation. Through this process 
platelet aggregates are dissolved, the in vivo bleeding time is regulated, carotid artery platelet thrombus 
formation is inhibited, and mice have been shown to be protected against postischemic cerebral stroke 
180. Additionally, various other ADAMTS family members have been shown to play functional roles in 
vascularization, however rather in controlling angiogenesis than regulating blood coagulation. Studies on 
Figure 2.18: Role of ADAMTS13 in platelet 
adhesion and TTP (adapted from 171) 
VWF multimers adhere to endothelial cells or 
to connective tissue in the vessel wall. 
Platelets bind to the A1 domain of vWF via 
GPIb. Shear force applied by the blood flow 
stretches vWF and exposes a cleavage site for 
ADAMTS13 in the A2 domain. Cleavage of 
vWF limits the growth of intravascular 
thrombi. 
Congenital or acquired ADAMTS13 deficiency 
allows excessive platelet deposition, causing 
microvascular thrombosis and TTP. 
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ADAMTS1 reported that the C-terminal spacer domain together with its 3 TSR1s exhibit anti-angiogenic 
properties by sequestering VEGF and blocking its binding to VEGF receptors 181. Also other ADAMTS family 
members such as ADAMTS2, 12 and 15 have been shown to have anti-angiogenetic properties mostly 
independent of their catalytic domains. Due to their anti-angiogenetic properties these proteinases have 
also been shown to act negatively on tumor growth and proliferation 182-184. Although the non-catalytic C-
terminal domains of various ADAMTSs have been shown to have anti-angiogenic functions, the substrate 
specificity and function of the catalytic domain with respect to angiogenesis is of equal if not bigger 
physiological relevance. In this regard ADAMTS1 is the family member with the most known and the best 
studied substrates relevant for angiogenesis 185. Proteolysis of thrombospondin1 and 2 by ADAMTS1 for 
example, promotes the release of anti-angiogenic TSR fragments with remarkable inhibitory 
consequences to wound healing and tumor angiogenesis 186. Not only the cleavage of thrombospondins 
by ADAMTS1 inhibits angiogenesis, but also the cleavage of the basement membrane glycoproteins 
nidogen-1 and -2 by ADAMTS1 results in vascular impairment and correlates with tumor suppressive 
activities in some cancers (Fig. 2.19) 187.  
As already mentioned most ADAMTSs have been shown to have anti-tumorigenic properties mostly due 
to their capability of inhibiting angiogenesis, but also by influencing cell adhesion, migration, proliferation 
and degradation or interaction with extracellular matrix components. Moreover, several ADAMTS genes 
have been found mutated or epigenetically silenced in specific tumors 188. This, however, distinguishes 
them strongly from MMPs where the large majority of the family members exhibit pro-tumorigenic 
properties and their expression often correlates with poor prognosis and shortened disease-free and 
overall survival. As already mentioned ADAMTS1 is capable of capturing and inactivating VEGF, by 
prohibiting its binding to the corresponding receptor. However ADAMTS4 is also able to capture and 
inactivate VEGF. Moreover ADAMTS4 was shown to inhibit phosphorylation of VEGF receptor 2 (VEGFR2) 
189. Furthermore, and consistent with ADAMTS angio-inhibitory capacities, it has been shown that 
ADAMTS2 decreases Erk phosphorylation levels in HUVEC cells 182. Other ADAMTS family members seem 
to inhibit Erk phosphorylation as well. For example ADAMTS12, which has been shown to inhibit Erk 
phosphorylation and tubulogenesis in MDCK cells upon stimulation with hepatocyte growth factor (HGF) 
190. Abrogation of Erk phosphorylation has also been linked to ectopic expression of ADAMTS15 in colon 
cancer cells and ADAMTS8 in epithelial and esophageal carcinoma cells 191, 192. ADAMTS9 another member 
of the family, can suppress tumor progression by inhibiting the activity of Akt/mTOR (Fig. 2.19) 193. Most 
ADAMTSs are expressed by the tumor cells themselves. However, it is noteworthy that some ADAMTSs 
can be also found expressed in stromal cells but not in cancer cells. This is the case for ADAMTS12, which 
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has been detected in cancer-associated fibroblasts but not in tumor cells of colon carcinoma samples. The 
presence of ADAMTS12 has been related to a stromal response aimed to control tumor progression, 
thereby it has emerged as a potential marker of good prognosis in this type of tumor 194.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19: Schematic representation of the antitumor effects mediated by ADAMTS metalloproteases 
(adapted from 188 and 192) 
ADAMTSs can be produced by stromal or tumor cells, and exert antitumor properties inhibiting angiogenic 
or lymphangiogenic processes. Additionally some family members, for example ADAMTS8, block tumor-
promoting signaling pathways. These effects may be dependent on the catalytic activity such as 
degradation of the extracellular components thrombospondin-1 and -2, and nidogen-1 and -2, or 
independent of the catalytic activity such as VEGF sequestration.  
 
Although they have been shown to have anti-angiogenic properties, ADAMTS1, 4 and 12 have been shown 
to be pro-tumorigenic as well. Although the proteolytic processing of thrombospondin1 by ADAMTS1 
inhibits angiogenesis, ADAMTS1 has been further shown to be involved in the shedding of heparin-binding 
epidermal growth factor (HB-EGF) and amphiregulin, and the activation of EGFR 195. Additionally, 
ADAMTS1 can facilitate the spreading of tumor cells through the degradation of versican, a predictor of 
metastatic relapse in human breast cancer 196. 
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ADAMTS4 and ADAMTS5 are proteoglycanases that increase the invasive potential of glioblastoma cancer 
cells through the degradation of brevican, a highly expressed proteoglycan in this type of malignant brain 
tumor 197. ADAMTS12 on the other hand can potentiate trophoblast invasion by regulating adhesion and 
invasion via a mechanism involving αvβ3 integrin and FAK phosphorylation (Fig.2.20) 198. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.20: Schematic representation of the pro-tumorigenic effects mediated by ADAMTSs (adapted 
from 188)  
ADAMTSs may cleave or induce the release or activation of pro-angiogenic factors (HB-EGF or 
amphiregulin), and digest extracellular matrix components (proteoglycans) to facilitate tumor cell 
spreading and metastasis. Pro-tumor effects elicited by ADAMTSs are protease-dependent. Additionally, 
ADAMTSs can induce the recruitment of fibroblasts involved in tumor growth.  
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That ADAMTSs can have both pro- and anti-tumorigenic functions depends on the cancer and the context. 
It also correlates with the processing and activity of the proteinase itself. ADAMTS1 and 4 both undergo 
autocatalytic processing, which affects the balance between pro-tumorigenic and anti-tumorigenic 
functions of this metalloproteinase 188, 199. The N-terminal 53-kDa catalytically active isoform of ADAMTS4 
for example promotes B16 melanoma angiogenesis in mice. In clear contrast, the catalytically inactive full-
length protein or different truncated fragments containing the C-terminal ancillary domains delay 
melanoma cell growth and angiogenesis 199. Also the interaction with other ECM proteins can influence 
the tumorigenic potential of ADAMTSs. ADAMTS12 was shown to interact with fibulin-2 and concomitant 
expression of both extracellular proteins considerably reduces pro-tumorigenic capacities of breast tumor 
cells 200. Fibulin-2, similarly to fibulin-1, may act as a pro-tumor or anti-tumor glycoprotein respectively 
201. For example, fibulin-2 drives malignant lung cancer progression but reduces breast cancer cell invasion 
202, 203. Therefore, fibulin-2 most likely acts as a modulator between tumor-promoting and anti-oncogenic 
roles associated to ADAMTS12.    
 
Members of the ADAMTS family are not only involved in the development and progression of various 
diseases, but play an important role in tissue reorganization during organ development and 
embryogenesis. 
ADAMTS1, 4, 5, 9, 15 and 20 are known versicanases. Versican is an essential ECM component during 
embryogenesis as it gives rise to a loose, hydrated hyaluronan-rich matrix that provides structural support 
while allowing dynamic remodeling during morphogenesis. It influences the adhesion, migration and 
proliferation of many cell types and versican-null mice die around E10 because of cardiac defects 204. 
Therefore versican turnover by ADAMTSs is essential during various developmental processes such as 
cardiac development, limb morphogenesis, palate formation, skin pigmentation and myogenesis 205-209. 
During heart formation, the initially immature versican-rich ECM is replaced by a collagen, proteoglycan 
and elastin-containing matrix. Adamts9-null mice die prior to gastrulation, but hemizygous Adamts9+/− 
mice have heart malformations resulting from intact versican accumulation 205.  
 
2.6.3 ADAMTS-like proteins  
 
The ADAMTS superfamily not only comprises of the 19 catalytically active members discussed in the 
previous chapter, but also includes 7 non-catalytic members known as ADAMTS-like (ADAMTSL) proteins. 
The structure of ADAMTSLs resembles the non-catalytic domains of ADAMTS proteinases, but they lack a 
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protease domain (Fig.2.21) 210. Although members of the ADAMTS superfamily, ADAMTSL proteins are 
neither proteinases, nor do they arise by alternative splicing of ADAMTS proteinase genes. ADAMTSL are 
not well characterized and not much is known so far about their function. However, they are fully secreted 
and are components of the ECM 211. It is hypothesized that ADAMTSL may have architectural or regulatory 
functions in the matrix independent of proteolytic activity. Mutations in a variety of ADAMTSL genes have 
been linked to severe human diseases. ADAMTSL2 has been shown to bind to latent TGF-β-binding 
protein-1 (LTBP1) and fibrillin-1 (FBN1) and mutations in the human ADAMTSL2 gene cause geleophysic 
dysplasia, a rare disorder that is characterized by high levels of TGF-β activity and resembles Weill-
Marchesani syndrome (WMS) 212. Moreover a homozygous ADAMTSL4 mutation was recently identified 
in isolated ectopia lentis (IEL) (dislocation of the ocular lens) 213. Interestingly, IEL is a major clinical feature 
of both WMS and Marfan syndrome, and dominant IEL can also be caused by FBN1 mutations in addition 
to ADAMTSL4 mutations  214. Therefore, the role of ADAMTSL2 and ADAMTSL4 in TGF-β regulation and 
maintenance of the lens, respectively, suggests that these ADAMTSL proteins may regulate fibrillin 
supramolecular assembly and/or architecture 211. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.21: Overview of mammalian ADAMTSL proteins (adapted from 211) 
The domain structure of each ADAMTSL is shown. The two forms of ADAMTSL1 shown are splice variants 
of the same gene. The long form of ADAMTSL1 composes a clade with ADAMTSL3. ADAMTSL4 and 
ADAMTSL6 contain a distinct clade in which TSR1 is split by an insertion.  
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2.6.4 ADAMTS16 
 
ADAMTS16 is one of the ADAMTS members without a known substrate and is therefore also called an 
orphan proteinase 140. Structurally ADAMTS16 is closely related to ADAMTS18 and contains 5 TSR1 repeats 
and a PLAC domain at its C-terminus. ADAMTS16 was first discovered and cloned in 2002 by Cal et al. 215.  
An expression analysis of various human embryonal and adult tissues showed that ADAMTS16 is 
expressed in fetal kidney and lung tissue and in adult brain and ovarian tissue. In addition very low 
amounts of ADAMTS16 were found in placenta samples 215. From its first discovery until know, not much 
more information on ADAMTS16 has become available. So far no substrate has been identified and its 
function within the ECM remains mainly unknown. Although studies showed that a recombinant 
ADAMTS16 construct comprised only of its protease domains, developed very weak aggrecanase activities 
154, it remains questionable if these findings are physiologically relevant. Studies addressing the regulation 
of ADAMTS16 expression found that ADAMTS16 is mainly expressed in the ovaries by the parietal 
granulosa cells of pre-ovulatory follicles. In fully differentiated luteinizing granulosa cells, follicle-
stimulating hormone (FSH) and forskolin induce expression of ADAMTS16, suggesting that it is regulated 
via the cAMP pathway 216. Mutations in the ADAMTS16 gene were associated with premature ovarian 
failure 217, 218, indicating that ADAMTS16 plays an important role during ovulation.  
Further studies using mouse embryonal kidney and gonad tissues and cell lines indicate the Adamts16 is 
transcriptionally regulated by the transcription factor Wilms tumor protein 1 (Wt1) and is involved in the 
branching process during kidney development 219. Moreover ADAMTS16 knockout rats showed 
morphological defects in the kidney associated with high amounts of protein in the urine in addition to 
impaired testis development resulting in low sperm production and sterility 220, 221. 
ADAMTS16 is not only relevant during kidney and testis development, but was linked to a variety of 
diseases. Tissue samples of OA patients showed increased expression levels of ADAMTS16 222, 223 where 
the main source of ADAMTS16 seems to be the synovium rather than the cartilage itself 223. Additional 
characterization of ADAMTS16 using in vitro cell culture assays showed that ADAMTS16 expression in 
chondrocytes is strongly increased in the presence of TGF-β. TGF-β mediated signaling most likely results 
in the activation of gene transcription by the two transcription factors Sp1 and Egr1 224. These factors were 
previously linked to TGFβ signaling mediated expression of other extracellular matrix genes 225, 226.  
Further mutations in the ADAMTS16 gene have been associated with a higher risk of developing high 
blood pressure 227. 
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Additionally ADAMTS16 was found to be overexpressed in esophageal squamous cell carcinomas 228 and 
ADAMTS16 gene mutations influence therapeutic outcome in ovarian cancer patients 229.  
Although ADAMTS16 seems to have a functional role in the development of certain diseases and in 
branching morphogenesis during development, the research done so far focused mainly on gene 
expression levels and stayed descriptive. So far no substrate has been identified and the mechanism by 
which ADAMTS16 regulates ovulation, contributes to osteoarthritis or other diseases remains unclear.   
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3. Aim of the Thesis  
 
ADAMTSs are a family of extracellular metalloproteinases that play key roles during tissue remodeling and 
regeneration, development and disease. However, their substrate variety and their functional roles in 
ECM turnover and cell signaling are not well understood for most of the family members. Their C-terminal 
domain varies strongly within the different family members and distinguishes them from MMPs and 
ADAMs. Moreover the C-terminal domain of ADAMTSs has a variety of functions, such as regulating 
activity, ECM binding and substrate recognition. Because of their strong C-terminal variability and the 
strong influence of the C-terminus on the overall function of ADAMTSs, C-terminal processing is a key 
element in regulating ADAMTS activity. Therefore certain members can have pro- and anti- tumorigenic 
properties depending on binding partners and C-terminal processing. This C-terminal variability makes 
them an ideal therapeutic target, because it allows the design of very specific binders to their C-terminus 
with minimal cross reaction with other family members or members of the MMP or ADAMs family. 
However to use them as an efficient therapeutic target, it is necessary to have an in depth understanding 
of their substrate specificity, and their biochemistry, especially with respect to C-terminal processing and 
the underlying mechanism of action.  
ADAMTS16 is an orphan member of the ADAMTS family. However, recent studies linked mutations in the 
ADAMTS16 gene to a variety of diseases such as blood pressure regulation and cancer. Additionally 
ADAMTS16 seems to play an important role during ovulation and spermatogenesis. Although ADAMTS16 
is physiologically relatively well characterized, knowledge of its biochemistry, substrates and underlying 
mechanisms of action is rather limited.  
The aim of this project was to identify a substrate for ADAMTS16, its mechanism of action and its influence 
on cellular morphology and behavior. For this we developed a novel mass spectrometry approach using a 
decellularized ECM for substrate identification. A second goal was to gain a better understanding of the 
ADAMTS16 biochemistry and the functional role of C-terminal processing. For our studies we used wild 
type ADAMTS16 constructs, but generated an active site mutant in addition as a control. Using the inactive 
mutant allowed us to further investigate the function of the C-terminal domain separately from the 
catalytic activity.  
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4. Results 
 
4.1 Manuscript  
 
 
 
 
“A selective extracellular matrix proteomics approach identifies fibronectin proteolysis by 
ADAMTS16 and its impact on spheroid morphogenesis “ 
 
 
Rahel Schnellmann, Ragna Sack, Daniel Hess, Douglas S. Annis, Deane F. Mosher, Suneel S. Apte and Ruth 
Chiquet-Ehrismann 
 
 
 
 
 
 
Accepted for publication April 2018 and in press with  
Molecular and Cellular Proteomics  
 
 
 
 
 
My contribution to this paper: 
For this study I developed the mass spectrometry approach used for substrate identification. I 
performed the production and purification of the decellularized ECM and collected and prepared 
the conditioned medium for mass spectrometry analysis. Together with Ragna Sack I analyzed 
the mass spectrometry data and identified the relevant potential substrates. I planned, 
performed and analyzed all cell culture and spheroid assays. I cloned all the used constructs and 
performed all RT-PCR experiments. With the help of Douglas Annis and Dean Mosher I performed 
the cleavage assays to prove that fibronectin is a substrate of ADAMTS16. I wrote the manuscript 
with the input of Suneel Apte.  
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5. Unpublished Results  
 
5.1 Materials and Methods  
 
All reagents and chemicals used in the following experiments were obtained from either Sigma Aldrich or 
Merck Millipore unless stated otherwise.  
 
Cell culture, cloning and transfection 
Human embryonic kidney HEK293-EBNA cells, African Green Monkey kidney cells COS-7 and the 
glioblastoma cell line LN229 were grown in DMEM medium supplemented with 10% FCS. The epithelial 
Madyn-Darby canine kidney type I cells (MDCKI) were grown in α-MEM supplemented with 10% FCS. All 
cell culture experiments were done in medium supplemented with 10% FCS unless stated otherwise.  
 
Mouse ADAMTS16 cDNA ORF clone (with ref. sequence NM_172053), was obtained from Creative 
Biogene (Shirley, NY). All constructs were C-terminally myc_His6 tagged and subcloned into pCEP_pu 
(Invitrogen, Carlsbad, CA). Cloning primers and protocols are described previously. Briefly truncated 
ADAMTS16-sh was amplified by PCR adding KpnI and NheI restrictions sites 5’ and a NotI restriction site 
3’. Additionally the construct was C-terminally myc_His6 tagged. The constructs was cloned into the 
pCEP_pu via the KpnI and NotI restriction sites (pCEP_pu_ADAMTS16-sh). WtADAMTS16 was amplified by 
PCR adding NheI and NotI restrictions sites 5’ and 3’ respectively and a C-terminal myc_His6 tag. 
WtADAMTS16 was cloned into pCEP_pu_ADAMTS16-sh via the NheI and NotI restriction sites, thereby 
replacing ADAMTS16-sh. All clones were verified by DNA sequencing. For vector maps and DNA sequences 
see Appendix.     
Human MMP14 cDNA ORF clone (with ref. sequence NM_008608.3) was obtained from Sino Biological 
(Sino biological Inc., Beijing, China). MMP14 was amplified by PCR adding a C-terminal HA tag and cloned 
into pCDNA-3.1 vector. The following primers were used: 5’- ACG TAA GCT TGC CAC CAT GTC TCC CGC CCC 
TCA ACC (forward primer) and 5’- ACG TGG ATC CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT AGA CCT 
TGT CCA GCA GCG AAC-3’ (reverse primer).  
 
COS-7, HEK-EBNA, MDCKI and LN229 cells were transfected using FuGENE® 6 (Roche, Basel, Switzerland) 
or jetPEI® DNA transfection reagent (Polyplus), respectively according to the manufacturers’ instructions. 
To obtain stably expressing cell lines, the cells were treated after transfection with puromycin for 14 days.  
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Protein analysis by western blotting 
Cell extracts and conditioned media were prepared in Laemmli loading buffer with or without 2-
mercaptoethanol, separated by SDS-PAGE and transferred to a nitrocellulose membrane. Amido black 
staining of the membranes was used to visualize bands as loading control. Blots were probed with the 
following antibodies: anti-MMP14 (diluted 1:2000 in 5% milkpowder/ TBS-T, rabbit polyclonal, ab88618, 
Abcam), anti-myc (diluted 1:100 in 5% milkpowder/ TBS-T, mouse monoclonal, Clone: 9E10, homemade 
FMI), anti-HA (diluted 1:10 in 5% milkpowder/TBS-T, mouse monoclonal, homemade FMI), anti-MMP3 
(diluted 1:1000 in 5% milkpowder/ TBS-T, rabbit monoclonal, EP1186Y, Abcam). The blots were further 
treated using horseradish peroxidase-conjugated secondary antibodies (1:10,000; MP Biomedicals, 
France) for detection with the ECL Western blotting System (Amersham, Switzerland), and exposed to 
Kodak X-ray film.  
 
MMP14 cleavage assay  
COS-7 cells were co-transfected with MMP14 and various ADAMTS16 constructs using jetPEI® DNA 
transfection reagent (Polyplus) according to manufacturers’ instructions. After transfection the cells were 
incubated under serum-free conditions for 24 h at 37°C. The cell lysate and conditioned medium were 
prepared in Laemmli loading buffer containing 2-mercaptoethanol and analyzed by western blot as 
described previously.  
 
MMP3 cleavage assay 
HEK-EBNA cells were co-transfected with MMP3 and either wtADAMTS16, ADAMTS16-EA or vector 
control using FuGENE® 6 (Roche, Basel, Switzerland) according to manufacturers’ instructions. After 
transfection cells were incubated under serum-free conditions for 24 h at 37°C. Conditioned medium was 
prepared in Laemmli loading buffer with or without 2-mercaptoethanol and analyzed by western blot as 
described above.  
HEK-EBNA cells were transiently transfected with MMP3. After 24 h of incubation under serum-free 
conditions, the conditioned medium was collected and incubated with purified recombinant ADAMTS16-
sh. 50 µl of conditioned medium containing MMP3 was incubated with ADAMTS16-sh in the presence or 
absence of 50 mM EDTA for 4 h at 37°C. The sample was prepared in Laemmli loading buffer without 2-
mercaptoethanol and analyzed by western blot as described above. 
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Immunofluorescence (IF) 
HEK-EBNA cells stably expressing wtADAMTS16 and ADAMTS16-EA were plated on 35×10 mm cell culture 
dishes with 4 inner rings (Greiner Bio-One GmbH, Germany) in DMEM supplemented with 10% FCS and 
EDTA-free protease inhibitor (cOmplete™, Mini Protease Inhibitor Cocktail, Sigma-Aldrich). Cells were 
incubated for 24 h at 37°C and fixed with Zinc Formal-Fixx™ (Thermo Fisher Scientific) for 30 minutes and 
permeabilized with 0.1% Triton X-100 for 5 minutes. Cells were incubated at room temperature with anti-
myc mouse monoclonal antibody (diluted 1:20 in PBS, Clone: 9E10) for 90 minutes and then incubated 
with Alexa488-labeled secondary antibody (diluted 1:1000 in PBS) for 60 minutes. Cell nuclei were stained 
using Hoechst staining solution (diluted 1:1000, Hoechst 33342 Solution, Thermo Fisher Scientific). Cells 
were mounted in Prolong Gold antifade reagent (Invitrogen, Switzerland) and images were taken using a 
Zeiss-Axioscope fluorescent microscope equipped with a 20X objective and Hamamatsu ORCA-ER camera.  
 
HEK-EBNA cells stably expressing wtADAMTS16, ADAMTS16-EA or vector control were seeded on 8-well 
glass chamber slides (Falcon Culture Slides, Thermo Fisher Scientific) previously coated with FN (30 µg/ml 
in PBS) and allowed to attach for 24 h at 37°C. Cells were fixed using 4% paraformaldehyde (PFA) for 20 
min at room temperature. Cells were stained using phalloidin (diluted 1:1000, Alexa Fluor™ 568 Phalloidin, 
Thermo Fisher Scientific). Samples were mounted in ProLong Gold with DAPI (Life Technologies, Carlsbad, 
CA) and imaged with a Leica TCS5 SPII confocal microscope. Images were acquired under identical camera 
settings and analysed using ImageJ software (U. S. National Institutes of Health, Bethesda, Maryland, 
USA). 
 
Mass spectrometry analysis  
To identify the additional proteins co-purified with ADAMTS16-sh, we performed an in gel digest and 
analyzed the samples by mass spectrometry (MS). 50 µl of ADAMTS16-sh protein elute, described in the 
manuscript, was separated by SDS-PAGE. The gel was further stained using ready-to-use protein stain 
based on colloidal coomassie dye G-250 (GelCode™ Blue Stain Reagent, Thermo Fisher Scientific). Protein 
bands were cut and the coomassie was excised by washing the gel pieces in 50 μL AmBic (25 mM 
NH4HCO3 in 50% acetonitrile) for 30 min at room temperature. Samples were reduced with tris(2-
carboxyethyl)phosphine (TCEP), alkylated with Iodoacetamide and digested with Trypsin overnight at 
37°C. Peptides were analyzed by liquid chromatography mass spectrometry (LTQ Orbitrap Velos, Thermo 
Fisher Scientific). The results were analyzed using Scaffold 4.4.8 software (Proteome Software, Portland, 
Oregon, USA). 
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Phage display 
To identify potential substrates of ADAMTS16 a commercially available phage library was used (NEB Ph.D 
7 phage display library, NEB). Purified ADAMTS16-sh and its inactive mutant ADAMTS16-sh-EA was used 
as template. The experiment was performed according to manufacturers’ instructions. Although the 
target protein was diluted in TBS buffer and not in NaHCO3 as recommended by the protocol. After three 
rounds of panning 20 clones were picked and sequenced. The 20 protein sequences were analyzed for a 
potential consensus sequence. A protein blast was performed with the resulting consensus sequence 
using NCBI/BLASTP (National Center for Biotechnology Information (NCBI), Bethesda MD). 
UniProtKB/Swiss-Prot was used as search database with a maximum of 500 target sequences. The search 
was restricted to human and mouse proteins. Only ECM proteins and the extracellular domain of 
membrane proteins were considered as potential substrates.   
 
Protein zymogram 
After reaching 90% confluency, MDCKI and HEK-EBNA cells stably expressing various ADAMTS16 
constructs were incubated under serum-free conditions for 48 h at 37°C. The conditioned medium was 
collected, concentrated and analyzed by zymography. For casein zymography, 2 ml of media was 
concentrated using amicon centrifugal filter units (Amicon Ultra-0.5 mL Centrifugal Filters, Merck 
Millipore)). 5 µg of total protein was loaded on a 10% polyacrylamide gel containing 0.1% casein. The gels 
were soaked in wash buffer (2.5% Triton X-100, 50 mM Tris (pH 7.5), 5 mM CaCl2, 1 uM ZnCl2) for 60 
minutes at room temperature to remove the SDS and incubated in reaction buffer (50 mM Tris-HCl (pH 
7.5), 5 mM CaCl2 and 1 uM ZnCl2) at 37°C overnight. Gels were rinsed again in distilled water, stained with 
0.5% Coomassie brilliant blue R-250 in 30% methanol and 10% acetic acid for 30 min, and destained with 
30% methanol and 10% acetic acid. Proteolytic activities appeared as clear bands of lysis against a dark 
background of stained casein.  
For gelatin zymography 2 ml of media form HEK-EBNA cell or MDCKI cells respectively was concentrated 
using amicon centrifugal filter units. 10 µg of total protein was loaded on a 10% polyacrylamide gel 
containing 0.1% gelatin. The same staining protocol as described above was used.  
 
Quantitative Reverse-Transcriptase PCR 
Total RNA was isolated using the RNeasy Plus Micro Kit (50) (Quiagen). RNA was reverse transcribed and 
relative ADAMTS16 mRNA levels normalized to TBP were measured using Platinum® SYBR® Green qPCR 
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SuperMix-UDG with ROX (Invitrogen). The following ADAMTS16 primers were used: 5’-CGC AAG AAA TAC 
ATG CCC CAG-3’ (forward primer) and 5’-AGA AGA GAG CGC TTA TGC CG-3’ (reverse primer). Real-time 
PCR was performed in StepOnePlus Real-Time PCR System (Applied Biosystems, Rotkreuz, Switzerland) 
using a standard cycling profile. All samples were run in duplicates. Endogenous ADAMTS16 mRNA 
expression levels were analyzed by the ΔCt method 230. Data represent means ± S.E.M from technical 
replicates. 
 
RNA in situ hybridization 
16.5 day-old (E16.5) mouse embryos and kidneys of newborn, 10 days, 4 week- and 8 week-old mice were 
fixed in 4% PFA at 4°C for 48h prior to paraffin embedding. Fresh 10 µm sections for the embryo tissue 
and 7 µm sections for the kidney tissue were used for in-situ hybridization using RNASccope (Advanced 
Cell Diagnostics, Newark, CA)) following the manufacturer’s protocol. All steps requiring incubation at 
40°C were performed in a HybEZ Oven (Advanced Cell Diagnostics). Tissue localization of specific probe 
against mouse Adamts16 mRNA (#474881, Advanced Cell Diagnostics) was detected with the RNAscope 
2.0 HD detection kit “RED”(Advanced Cell Diagnostics).  
 
Boyden chamber cell migration assay 
Directed migration of MDCKI and HEK-EBNA cells stably expressing various ADAMTS16 constructs was 
analyzed using transwell polycarbonate membrane inserts (6.5 mm; Corning, Amsterdam, The 
Netherlands) with 8 μm pore size. The transwell inserts were either left untreated or the lower membrane 
site was FN coated (100 µg/ml in PBS) prior to use. 3.5 * 104 cells were plated in 100 μl serum-free DMEM 
into the transwell inserts. The lower chamber was filled with 600 μl 10% FCS/DMEM. Cells were incubated 
at 37°C and were allowed to migrate across the transwell filters for 24 h. Migrated cells were fixed and 
stained with crystal violet. 4 Images/ insert were taken using a Zeiss-Axioscope fluorescent microscope 
equipped with a 10X objective and Hamamatsu ORCA-ER camera. Migration was quantified by measuring 
the area covered by migrated cells using ImageJ software (U. S. National Institutes of Health, Bethesda, 
Maryland, USA). Data represent means ± S.E.M from technical replicates. 
 
Cell proliferation assay 
Proliferation rates of MDCKI cells stably expressing wtADAMTS16, ADAMTS16-EA and vector control  and 
LN229 cells transiently expressing wtADAMTS16, ADAMTS16-EA and vector control were determined 
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using the MTT cell proliferation assay kit (Vybrant® MTT Cell Proliferation Assay Kit, Thermo Fisher 
Scientific). MDCKI and LN229 cells were plated in triplicates on 96-well microtiter plates (PerkinElmer) 
in 10% FCS/DMEM at 3*103 cells/well and 5*103 cells/well, respectively, were incubated at 37°C and 
allowed to proliferate for 24 h, 48 h, 3 days, 4 days, 5 days, 6 days and 7 days. At each time point cells 
were labelled with the MTT reagents following the manufacturer’s instructions and the absorbance was 
measured at 540 nm using an absorbance spectrophotometer (PowerWave HT microplate 
spectrophotometer, BioTeK). Data represent means ± S.E.M from technical triplicates.  
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5.2 Results 
  
5.2.1 ADAMTS16 is C-terminally processed and forms high order oligomers  
 
Due to the observed C-terminal processing of wtADAMTS16, HEK-EBNA cells stably expressing 
wtADAMTS16 and ADAMTS16-EA were treated with an EDTA-free protease inhibitor cocktail and analyzed 
for secretion and accumulation of ADAMTS16 by western blot and immunofluorescence (IF). Cells treated 
with protease inhibitor strongly accumulate ADAMTS16 within the secretory pathway, mainly within the 
trans-Golgi network (TGN). This indicates that ADAMTS16 is fully translated and the C-terminus is either 
cleaved by proteases within the TGN, in the secretory pathway or extracellularly in close proximity to the 
cell surface (Fig. 1A). Analysis of the cell lysate of inhibitor treated cells by western blot conforms the 
accumulation of full length ADAMTS16. Due to the extremely low amount of full length ADAMTS16 in the 
cell lysate of untreated cells we can conclude that under normal conditions ADAMTS16 is very efficiently 
C-terminally processed shortly after translation. Moreover, although we treated the cells with protease 
inhibitor we still could observe a low amount of mature ADAMTS16 indicating that the protein convertase 
furin, responsible for prodomain processing was not completely inhibited, or another protease is 
processing the prodomain as well (Fig. 1B).    
 
 
 
 
 
 
 
 
 
Figure 1: Upon treatment with EDTA-free protease inhibitor strong accumulation of ADAMTS16 in the 
secretory pathway was observed. A. HEK-EBNA cells stably expressing wtADAMTS16 or ADAMTS16-EA 
were treated with protease inhibitor. After 24 h the cells were stained for ADAMTS16 expression using an 
anti-myc antibody against the C-terminal tag of ADAMTS16 (green). Strong accumulation of ADAMTS16 
within the trans-Golgi network could be observed (white arrows). Scale bars 50 µm B. Western blot 
analysis of cell lysate of protease inhibitor treated HEK-EBNA cells. The blot was probed with anti-myc 
antibody. Strong accumulation of ADAMTS16 could be observed within the cell lysate of inhibitor treated 
cells. Zymogen (Z) and mature (M) ADAMTS16 are indicated by black arrows. Amido black staining of the 
membrane was used to visualize protein bands as loading control. 
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A recent publication by Kosasihet al. on ADAMTS5 showed that the C-terminal ancillary domain can 
influence the protease activity without being covalently attached to the protease domain. They showed 
that ADAMTS5 is a higher order oligomer and that oligomerization is required for full aggrecanase activity. 
However the ancillary domain can block full length ADAMTS5 oligomerization and therefore inhibit 
ADAMTS5 activity. To show the effect of the ancillary domain on ADAMTS5 activity in vivo they compared 
the aggrecanolysis in cartilage explanted from mice that were either heterozygous for the ADAMTS5Δcat 
(TS5Δcat) mutation (TS5+/Δcat) or the ADAMTS5 null mutation (TS5+/−). TS5Δcat mice express the full 
suite of ancillary domains but lack ADAMTS5 activity, where ADAMTS5 null mice expressed neither 
catalytic nor ancillary domains. Where the TS5+/− mice had the same level of aggrecanase activity as wild 
type mice, TS5+/Δcat mice had significantly reduced aggrecanase activity. This result suggested the 
possibility of an interaction between wild type and mutant ADAMTS5 molecules in TS5+/Δcat cartilage, in 
which binding of the mutant TS5Δcat protein, with its full set of ancillary domains, to wild type ADAMTS5 
inhibits enzyme activity in a dominant-negative manner. 231.   
 
Based on the published results on ADAMTS5 oligomerization we tested whether ADAMTS16 forms 
oligomers in vitro as well. For this we analyzed the supernatant of HEK-EBNA cells transiently expressing 
various ADAMTS16 constructs under reducing, and non-reducing conditions, by western blot. Because of 
the strong C-terminal processing of wtADAMTS16 we were not able to detect any full length protein in 
the conditioned medium using antibodies against the C-terminal myc-tag. Therefore, we used the short 
form of ADAMTS16 lacking the C-terminal TSR1 and PLAC domains (ADAMTS16-sh, construct details are 
described in the manuscript) and its inactive mutant (ADAMTS16-sh-EA) to screen for oligomerization. We 
could observe the formation of higher order oligomers in the conditioned medium of cells expressing 
ADAMTS16-sh. Further we observed that oligomerization is not dependent on enzyme activity, because 
the inactive mutant ADAMTS16-sh-EA showed the formation of oligomers as well. However, we observed 
a lower overall amount of secreted ADAMTS16-sh-EA (Fig.2A).  
To investigate the influence of the C-terminal domain on oligomerization we co-expressed wtADAMTS16 
and its inactive mutant ADAMTS16-EA together with the truncated constructs ADAMTS16-sh and 
ADAMTS16-sh-EA. The presence of full length ADAMTS16 neither interferes with the oligomer formation 
of ADAMTS16-sh nor its inactive mutant ADAMTS16-sh-EA. However, we could observe a reduction in 
oligomer formation by ADAMTS16-sh in the presence of active ADAMTS16, but not in the presence of 
ADAMTS16-EA (Fig. 2B). As expected, we could not detect any bands in the conditioned medium of cells 
co-expressing wtADAMTS16 and ADAMTS16-EA (Fig. 2B). Moreover we could see strong C-terminal 
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processing of ADAMTS16 in the cell lysate of transiently transfected cells. Co-expression of wtADAMTS16 
with either inactive ADAMTS16-sh-EA or ADAMTS16-EA did not influence the C-terminal processing, 
indicating that neither the truncated ADAMTS16-sh-EA nor the full length inactive ADAMTS16-EA interfere 
with the activity of ADAMTS16 and its ability for autoproteolysis. Additionally neither ADAMTS16-EA nor 
ADAMTS16-sh-EA interfered with the activity and the ability of other proteinases to C-terminally process 
ADAMTS16. (Fig.2B).    
 
Because of its C-terminal processing it was not possible to purify full length ADAMTS16. Therefore we 
decided to express and purify the C-terminally truncated ADAMTS16-sh, as described previously. The 
eluted protein fractions containing purified recombinant ADAMTS16-sh were analyzed by SDS-Page. 
Beside the most abundant band corresponding to ADAMTS16-sh at approximately 75 kDa, we observed 
several other bands at lower molecular weights. To investigate whether these bands are degradation 
products of ADAMTS16-sh, or other co-purified proteins, we performed an in gel digest and analyzed the 
fractions by mass spectrometry (MS). We could not see any degradation of ADAMTS16-sh, instead we 
found a couple of human proteins co-purified with ADAMTS16-sh, such as clusterin (CLUS) and heat shock 
70 kDa protein 1A/1B (HSP71). Both proteins are known chaperones where CLUS can act intracellularly as 
well as in the extracellular space. Additionally CLUS is involved in the internalization of bound proteins via 
cell surface receptor binding. Further we identified tubulin beta chain (TBB5) and zinc transporter ZIP10 
(S39AA) amongst the co-purified proteins (Fig. 3A). This either indicates that the identified co-purified 
proteins bind unspecifically to the Ni-column or bind non-covalently to ADAMTS16 and are therefore co-
purified with the proteinase.    
Moreover we had a closer look at the purified ADAMTS16-sh. We did not find any peptides belonging to 
the N-terminal propeptide indicating that the prodomain of purified recombinant ADAMTS16-sh is fully 
removed by furin prior to or after secretion and that the proteinase should therefore be fully active (Fig. 
3B).  
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Figure 2: Western blot analysis of supernatant of transiently transfected HEK-EBNA cells showed 
oligomerization of ADAMTS16 A. The conditioned medium of transiently transfected cells with the C-
terminally truncated ADAMTS16-sh and its inactive mutant (ADAMTS16-sh-EA) showed oligomerization 
of the catalytic domains of ADAMTS16 (red arrow). The ADAMTS16-sh-EA showed a lower overall amount 
of secreted protein and oligomerization. The conditioned medium was analyzed by western blot under 
reducing and non-reducing conditions. All constructs are C-terminally myc-tagged and an anti-myc 
antibody was used for detection of ADAMTS16. Amido-black staining of the membrane was used as 
loading control. B. The C-terminally truncated constructs ADAMTS16-sh and ADAMTS16-sh-EA were 
either co-transfected with wtADAMTS16 or its inactive mutant ADAMTS16-EA respectively. The cell lysate 
as well as the conditioned medium were analyzed by western blot under reducing and non-reducing 
conditions. The presence of the full length ADAMTS16 did not influence the ability of the truncated 
ADAMTS16-sh, or ADAMTS16-sh-EA to form oligomers (red arrow). The zymogen (Z) and mature (M) 
forms of wtADAMTS16 (FL) and the truncated ADAMTS16-sh (Sh) are indicated by black arrows. C-terminal 
processing is indicated by asterisks and the ADAMTS16 constructs just comprising of the C-terminal TSR1 
and PLAC domain (ADAMTS16-CT) is indicated by a black arrow labelled CT.  
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Figure 3: In gel digest and MS analysis of purified mouse ADAMTS16-sh by MS. A. 50 µl of the main protein 
elute of purified ADAMTS16-sh was separated by 10% SDS-Page. The visible bands were cut and an in gel 
digest was performed for protein identification by MS. Clusterin (CLUS), tubulin beta chain (TBB5), zinc 
transporter ZIP10 (S39AA) and heat shock 70 kDa protein (HSP71) were identified as being co-purified 
with ADAMTS16. The data was analyzed using Scaffold software B. The purified recombinant ADAMTS16-
sh was analyzed by MS for peptide coverage. No peptides belonging to the prodomain were identified. 
The red box marks the furin cleavage site RHKR. The blue box indicates the last three amino acids of the 
truncated ADAMTS16-sh. The data was analyzed using Scaffold software.    
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5.2.2 Phage display for identification of ADAMTS16 substrates  
 
In a first attempt we tried to identify substrates by phage display. For this we used a commercially 
available phage library (NEB Ph.D 7 phage display library), where each phage displays a 7 amino acid long 
peptide (Fig. 4). As target proteins, purified mouse ADAMTS16-sh and its inactive mutant ADAMTS16-sh-
EA were used. The consensus sequence KVWXXPZ and XMMHHPH where X can be any amino acid and Z 
has to be either R, N or Q, could be identified in both targets independently from each other. A protein 
blast was performed using the consensus sequences to screen for potential binding partners. The search 
was restricted to extracellular and membrane proteins. Using those criteria, 10 potential binding partners 
and therefore potential substrates for ADAMTS16 could be identified (Table 1). Some proteins such as 
MMP14 were further analyzed for their ability to be a substrate of ADAMTS16. Additionally the identified 
binder FN was proven to be a substrate of ADAMTS16. Interestingly most glycoproteins and proteoglycans 
identified by phage display have the same overlapping consensus sequence WXXPZ. This could be a shared 
binding motif for ADAMTS16 and or other members of the ADAMTS family.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic overview of the phage display workflow. Recombinant ADAMTS16-sh was used as 
target. After 3 rounds of panning 20 clones were send for sequencing.    
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Protein Name Consensus Sequence Matching Sequence AA position 
Jagged 1 KVWXXPZ KVWCGPR 894-900 
 
Usherin KVWXXPZ VWVTPR 3676-3681 
 
MMP14 KVWXXPZ KVWEGIPESPR 454-464 
 
Laminin subunit alpha 5 KVWXXPZ WGFPN 1481-1485 
 
Tenascin KVWXXPZ WKGPN 180-184 
 
Collagen alpha-1 (V) KVWXXPZ WVDPN 1655-1659 
 
Fibronectin KVWXXPZ WTPPR 1016-1020 
 
Aggrecan KVWXXPZ WEEPR 2098-2102 
 
Neurocan KVWXXPZ WDRPQ 1216-1220 
 
ADAMTS18 MMHHPHX HHPH 197-200 
 
Table 1: Identified binders of ADAMTS16-sh. A protein blast was performed with the identified consensus 
sequences. Only ECM proteins and the extracellular domains of membrane proteins were considered as 
potential binders. The overlapping amino acids (AA) in the potential binding partners are marked in bold.  
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5.2.3 ADAMTS16 potentially processes MMP14 and MMP3  
 
To see whether MMP14 is a substrate of ADAMTS16, C-terminally HA-tagged MMP14 was co-expressed 
with various ADAMTS16 constructs in COS-7 cells. In addition to the anti-HA antibody recognizing the C-
terminus of MMP14, we used an anti-MMP14 antibody specific to the N-terminal domains of MMP14. 
Alternatively, to see whether ADAMTS16 is processed by MMP14, we also analyzed the cell lysate and 
conditioned medium using an anti-myc antibody recognizing the tagged C-terminus of ADAMTS16. As 
control, COS-7 cells were either transfected with MMP14 alone or in combination with inactive 
ADAMTS16-EA. Although we could not see any cleavage products in the conditioned medium using anti-
MMP14 antibody we found a profound reduction in the intensity of a protein band at approximately 50 
kDa when analyzing the cell lysate for MMP14 cleavage products (Fig. 5A). Moreover we observed high 
molecular weight bands in the lysate of cells co-expressing MMP14 and the inactive ADAMTS16 mutants, 
using anti-HA antibody (Fig. 5B). Interestingly the possible degradation of MMP14 by ADAMTS16 seems 
to be independent of its C-terminus, because the same results were obtained by using ADAMTS16-sh 
instead of wtADAMTS16.  Further we neither observed any bands in the cell lysate, nor in the conditioned 
medium of co-expressing cells, indicating degradation of ADAMTS16 by MMP14 when staining with anti-
myc antibody (Fig. 5C). However, we observed the secretion of the inactive zymogen of ADAMTS16-sh 
and ADAMTS16-sh-EA into the conditioned medium. This observation is unique to COS-7 cells and did not 
occur using ADAMTS16-sh expressing HEK-EBNA cells. Additionally a faint band corresponding to the 
wtADAMTS16 zymogen could be observed in the conditioned medium. Again secretion of full length 
ADAMTS16 could not be observed using HEK-EBNA cells (Fig. 5C). However, the secretion of the 
ADAMTS16 zymogen does not seem to correlate with the expression of MMP14, but seems to be COS-7 
cell specific.   
Due to the fact that MMP14 directly activates MMP2, measuring the activity of MMP2 via gelatin 
zymography gives valuable information about the activity of MMP14. Because COS-7 cells do not express 
endogenous MMP14 232 we used HEK-EBNA cells and MDCKI cells stably transfected with various 
ADAMTS16 constructs to perform a gelatin zymography. However, we could not detect any changes in 
MMP2 activity neither in HEK-EBNA cells nor in MDCKI cells (Fig. 6). Therefore, we conclude that 
ADAMTS16 does not have a direct influence on MMP14 activity, or the effects are too small to be detected 
by zymography. Additionally, no changes in MMP9 activity could be observed in HEK-EBNA cells expressing 
wtADAMTS16 compared to vector control.  
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Figure 5: Cell lysate of COS-7 cells co-expressing MMP14 with wtADAMTS16 or ADAMTS16-sh and their 
corresponding active site mutants analyzed by western blot shows potential cleavage of MMP14 by 
ADAMTS16. A. Cell lysate was analyzed for N-terminal MMP14 cleavage products using an anti-MMP14 
antibody against the N-terminus of MMP14. The black arrows indicate the zymogen (Z) and the mature 
(M) form of MMP14. The asterisk indicates a potential degradation of MMP14 by wtADAMTS16 and 
ADAMTS16-sh. B. Cell lysate was analyzed for C-terminal MMP14 cleavage products using an anti-HA 
antibody against the C-terminus of MMP14. The black arrows indicate the zymogen (Z) and the mature 
(M) form of MMP14. Red arrow indicates a high molecular weight band observed only if MMP14 is 
expressed alone or in combination with the inactive mutants ADAMTS16-EA and ADAMTS16-sh-EA. C. 
Western blot analysis of conditioned medium and cell lysate for C-terminal ADAMTS16 cleavage products. 
The black arrows indicate the zymogen of wtADAMTS16 and its corresponding mutant ADAMTS16-EA 
(Z_FL) and the zymogen of the truncated ADAMTS16-sh and its inactive mutant (Z_Sh) as well as the 
mature form of ADAMTS16-sh (M_Sh).   
90 
 
 
 
 
 
 
 
 
 
 
Figure 6: Gelatin zymogram of HEK-EBNA cells and the epithelial cell line MDCKI stably expressing various 
ADAMTS16 constructs. The black arrows indicate the bands corresponding to MMP2 and MMP9 
respectively. The cells were incubated for 48 h under serum free conditions, the conditioned medium was 
concentrated and 10 µg overall protein was loaded on the gel.  
 
Because we previously showed that N-terminal FN cleavage and the so released 30 kDa N-terminal heparin 
binding domain of FN can increase MMP3 expression in MDCKI cells and because of indications of MMP14 
processing by ADAMTS16, we aimed to see whether ADAMTS16 can influence MMP3 activity on a protein 
level in addition to increased expression. Therefore we co-expressed ADAMTS16 with MMP3 in HEK-EBNA 
cells and analyzed the conditioned medium for potential MMP3 cleavage. However, it was not possible to 
see any cleavage products of MMP3 by western blot, neither under reducing nor under non-reducing 
conditions. Interestingly we could however, observe a reduction of MMP3 protein levels in the 
conditioned medium of cells co-expressing MMP3 with wtADAMTS16 (Fig. 7A). To further investigate 
whether ADAMTS16 is processing MMP3, we incubated purified ADAMTS16-sh with conditioned medium 
of MMP3 expressing HEK-EBNA cells in the presence or absence of EDTA. Although we observed a second 
MMP3 band in the sample incubated with active ADAMTS16-sh it remains unclear whether this is really a 
cleavage product of MMP3 (Fig. 7B). As a last attempt to investigate whether ADAMTS16 influences 
enzyme activity of MMP3 we performed a casein zymogram using MDCKI cells stably expressing 
ADAMTS16. We could see an increase in MMP3 protein levels in the conditioned medium of wtADAMTS16 
expressing cells. Moreover we observed an increase in pro-MMP3 in the conditioned medium of cells 
expressing the inactive mutant ADAMTS16-EA. This indicates that ADAMTS16-EA binds to MMP3 but does 
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not enzymatically process it. Additionally ADAMTS16-EA binding may prevent MMP3 from being 
processed by other proteinases (Fig. 7C).     
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Western blot analysis and casein zymogram showed that ADAMTS16 is processing and 
influencing the activity of MMP3. A. Conditioned medium of HEK-EBNA cells co-transfected with MMP3 
and ADAMTS16 was analyzed by western blot under reducing and non-reducing conditions. The blot was 
probed with anti-MMP3 antibody to stain for MMP3 cleavage products. Strong reduction of MMP3 levels 
were observed in conditioned medium of cells co-expressing MMP3 with wtADAMTS16 (black arrow). B. 
Incubation of purified recombinant ADAMTS16-sh with conditioned medium of MMP3 expressing cells in 
presence or absence of EDTA. A second MMP3 band could be observed in conditioned medium in 
presence of active ADAMTS16-sh (black arrow). C. Casein zymogram using conditioned medium of MDCKI 
cells stably expressing ADAMTS16 showed increase in MMP3 levels in cells expressing wtADATMS16. 
Additionally increase in pro-MMP3 could be observed in the medium of cells expressing ADAMTS16-EA.  
The cells were maintained under serum free conditions for 48 h, the medium was concentrated and 5 µg 
of protein was loaded on the gel.  
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5.2.4 ADAMTS16 is expressed in various cancer cell lines and during development 
 
Various cancer cell lines were tested for endogenous ADAMTS16 expression by RT-PCR. Not surprisingly 
ADAMTS16 was not expressed in the non-tumorigenic HEK-EBNA cells. As already published ADAMTS16 
is endogenously expressed in human brain tissue 215, therefore we also analyzed mRNA from human brain 
tissue and found relatively strong expression of ADAMTS16. Compared to the relative ADAMTS16 mRNA 
expression in human brain tissue the glioblastoma cell lines U343 and LN229 showed increased 
expression, where most other brain tumor cell lines showed reduced ADAMTS16 expression. Additionally 
various other cancer cell lines of different origin showed endogenous expression of ADAMTS16 (Fig.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: RT-PCR analysis of various cancer cell lines for endogenous ADAMTS16 mRNA expression. The 
data was normalized to the housekeeping gene TBP. Additionally the endogenous ADAMTS16 mRNA levels 
of the non-tumorigenic HEK-EBNA cell line and of total human brain tissue was analyzed in addition to the 
cancer cell lines. Each bar represents the mean ± S.E.M from technical replicas.   
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In addition to cancer cell lines we analyzed the expression of Adamts16 during development by in situ 
hybridization. Therefore we analyzed the tissue of 16.5 day (E16.5) old mouse embryos. We found 
Adamts16 expression in the glomeruli and the tubular epithelial cells of the kidney, around the larger 
blood vessels of the liver, in the epithelial cells of the pancreas and the testis, in brain tissue, in the cells 
of the peritoneum and in stromal cells within the connective tissue around the intestine and colon. Further 
we found Adamts16 to be expressed during cranio facial development, most likely within structures 
further developing into teeth. We also found Adamts16 expression within the developing limbs, however, 
we could not clearly elucidate by the images whether Adamts16 is expressed by cells of the tendons, or 
nerve cells. To determine more precisely which cell linage exactly expresses Adamts16 would require 
further investigations (Fig. 9).  
 
 
 
 
 
 
 
 
 
 
 
 Figure 9: In situ hybridization of embryonal tissue at time point E16.5 shows strong expression of 
Adamts16 mRNA (red) within the kidney glomeruli (G) and tubular epithelial cells (T). Further Adamts16 
expression was observed in the limbs, around the large blood vessels of the liver, the testis and the 
pancreas. Additionally we found expression of Adamts16 within the peritoneum and by stromal cells 
within the connective tissue around the intestine and colon (black arrows). Adamts16 is further expressed 
by structures most likely developing into teeth (black arrows). Scale bars 100 µm.  
 
Because previous studies showed a possible involvement of ADAMTS16 during kidney development and 
branching 219, 221 we had a closer look at Adamts16 expression in the kidney at different stages of 
development. We found that Adamts16 is already expressed at E10.5, which is an early stage of kidney 
development, where the kidney can be seen as an S shaped body. Adamts16 expression remains 
constantly high during embryogenesis until birth (Fig. 10A). We also analyzed postnatal kidney tissue of 
mice. We could observe a very strong Adamts16 expression directly after birth within the glomeruli and 
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the renal tubular epithelial cells, similar to the kidney at time point E16.5. When the mice reach the age 
of 10 days the expression of Adamts16 is still very high. However, the expression is reduced when the 
mice reach adulthood. After 4 and 8 weeks the expression is already relatively low and strongly localized 
within and in close proximity to the cells of the glomeruli (Fig. 10B). Adamts16 expression therefore 
strongly decreases upon aging. This indicates that ADAMTS16 may play a major role during kidney 
development and is required for tissue remodeling during organ development and growth, but most likely 
does not have a major function in tissue maintenance in adult kidneys.  
 
 
 
 
 
 
    
  
Figure 10: In situ hybridization for Adamts16 
expression during kidney development and 
maturation. A. Tissues of mouse embryos at 
time point E10.5 and E16.5 were analyzed 
for Adamts16 mRNA expression (red). At 
time point E10.5 Adamts16 expression can 
be seen in the S-shaped body of the 
developing kidney (black arrows). At time 
point E16.5 Adamts16 is expressed in the 
glomeruli (G) and the renal tubular epithelial 
cells (T). Scale bars 100 µm. The boxed areas 
are 2X magnifications of the left picture. B. 
Tissue of new born and adult mice was 
analyzed for Adamts16 mRNA expression 
(red). After birth (p0) and at the age of 10 
days (p10) high Adamts16 expression can be 
observed in the kidney tissue, especially in 
cell of the glomeruli (G) and the tubular 
epithelial cell (T). After 4 and 8 weeks the 
expression is very low and can only be seen 
within the glomeruli (G) and in cells close to 
it. Scale bars 100 µm. The boxed areas are 
2X magnifications of the left image.   
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5.2.5 ADAMTS16 affects cell migration and proliferation 
 
To analyze the influence of ADAMTS16 on cell migration and proliferation we used a variety of different 
cell types either stably or transiently expressing ADAMTS16. In the first assay, we coated glass chamber 
slides with FN and seeded HEK-EBNA cells stably expressing wtADAMTS16, ADAMTS16-EA or vector only 
on top of the FN. After 24 h the cells were fixed and the actin skeleton was stained with phalloidin. Cells 
expressing wtADAMTS16 have markedly reduced amounts of filopodia compared to cells either 
expressing the inactive ADAMTS16-EA or vector only (Fig. 11A). Additionally, we used a Boyden chamber 
assay to evaluate the migration potential of ADAMTS16 expressing cells. For this we let the cells migrate 
towards 10% FCS on either untreated filters, or on filters where the lower filter side was FN coated. HEK-
EBNA cells showed no migration on untreated filters. However, HEK-EBNA cells stably expressing 
wtADAMTS16 showed a very strong migration on filters where the lower side was coated with FN. Cells 
expressing the truncated ADAMTS16-sh also showed increased migration, however, less strong than the 
wtADAMTS16 cells. Nevertheless, cells expressing the inactive full length ADAMTS16-EA showed a similar 
migration rate than cells expressing ADAMTS16-sh, indicating a contribution of the C-terminus of 
ADAMTS16 to cell migration in HEK-EBNA cells. In addition to HEK cells we also analyzed MDCKI cells stably 
expressing ADAMTS16 for their migration behavior on untreated and FN coated filters. MDCKI cells 
showed a stronger overall migration compared to HEK-EBNA cells towards FCS. However, no differences 
could be observed between untreated und FN coated filters with respect to MDCKI cell migration. Under 
both conditions a stronger migration of wtADAMTS16 and ADAMTS16-sh expressing cells could be 
observed, although the differences were not as dramatic as in HEK cells. Additionally the cells expressing 
inactive ADAMTS16-EA did not show an increased migratory behavior, as is the case for HEK cells (Fig. 
11B). In addition to cell migration we had a look at cell proliferation of ADAMTS16 expressing cells. For 
this we used the glioblastoma cell line LN229 and the epithelial MDCKI cells. LN229 cells transiently 
expressing wtADAMTS16 showed a massively reduced proliferation after 7 days in culture. However, no 
difference in cell proliferation could be observed for ADAMTS16 expressing MDCKI cells (Fig. 11C). These 
findings indicate that the effects of ADAMTS16 expression on cell proliferation and migration strongly 
depend on the cell type and not only on the ADAMTS16 expression itself.  
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Figure 11: MDCKI, HEK-EBNA and LN229 cells overexpressing wtADAMTS16 and ADAMTS16-sh showed 
distinct proliferation rates and migration behaviors. A. HEK-EBNA cells stably expressing wtADAMTS16, 
ADAMTS16-EA and vector control were seeded on FN coated glass chamber slides. The actin 
cytoskeleton was stained with phalloidin. Large amounts of long filopodia in vector control and cells 
expressing the inactive ADAMTS16-EA could be observed, where cells expressing wtADAMTS16 
showed reduced filopodia formation. Scale bar 50 µm. Boxed areas are 4X magnifications of the upper 
pictures. B. MDCKI and HEK-EBNA cell were allowed to migration towards 10% FCS for 24 h. The lower 
filter side was either left untreated or coated with 100 µg/ml FN. Migration was quantified measuring 
the cell covered area of the lower filter side. Stronger overall migration of MDCKI cells expressing 
wtADAMTS16 and ADAMTS16-sh was observed. Additionally strong migration of HEK-EBNA cells 
expressing wtADAMTS16 and ADAMTS16-sh on FN coated filters could be observed. Each bar 
represents the mean area ± S.E.M from technical replicates. Representative photos of fixed and stained 
cells that have migrated to the lower side of the filter are shown below the bar graph. C. Stably 
expressing MDCKI cells or transiently transfected LN229 cells were seeded into 96 well chambers and 
cell proliferation was assessed by using a MTT cell proliferation assay. Strong reduction in cell 
proliferation in wtADAMTS16 expressing cells after 7 days in culture could be observed. Each bar 
represents the mean area ± S.E.M from technical triplicates.  
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6. Discussion and Future Directions 
 
ADAMTS16 is an orphan member of the ADAMTS family. Although its physiological role during 
development and diseases has been addressed in a variety of different studies, its substrates and 
underlying mechanism of action remained so far unknown.  
Therefore we aimed to characterize ADAMTS16, identify possible substrates and its mechanism of action. 
In the present work we discovered that ADAMTS16 cleaves FN and that the released 30 kDa N-terminal 
heparin binding domain of FN can increase MMP3 expression in MDCKI cells. Moreover we observed 
strong C-terminal processing of ADAMTS16 in vitro. Analyzing the cell-free ECM of HEK-EBNA cells stably 
expressing ADAMTS16 showed that ADAMTS16 is, at least to some extent, secreted and processed 
extracellularly with the C-terminus remaining bound to the ECM. However, we could not conclusively 
assess whether ADAMTS16 is exclusively C-terminally truncated extracellularly, or if it is also processed 
intracellularly within the secretory pathway. Treatment with protease inhibitors showed an accumulation 
of full length ADAMTS16 in the trans-Golgi network. Moreover in the absence of protease inhibitors 
ADAMTS16 is barely detectable within the cell lysate. This findings indicate that ADAMTS16 is very 
efficiently C-terminally truncated directly after translation. Additionally we showed that ADAMTS16 has 
autocatalytic abilities and is able to C-terminally truncate itself. Because we observed C-terminal 
fragments in the cell lysate of cells expressing inactive ADAMTS16-EA, we have strong proof that at least 
one other proteinase is involved in the C-terminal processing of ADAMTS16. Nevertheless, we were 
neither able to identify the responsible proteinase nor the exact cleavage site. This would require further 
investigations. Further we observed differences in C-terminal processing between different cell lines. We 
could not detect any full length ADAMTS16 in the medium of LN229 cells, MDCKI cells or HEK-EBNA cells. 
However we detected very low amounts of full length ADAMTS16 in conditioned medium of COS-7 cells. 
Interestingly the band size corresponded rather to the zymogen form of ADAMTS16 and not the furin-
processed mature form of ADAMTS16. This observation, which seems to be very cell type specific, in this 
case COS-7 cells, might have several reasons. Due to the fact that we only observed the zymogen form in 
the medium but not the mature form of ADAMTS16, might mean that furin activation is not as efficient 
as it is in other cell lines and, as a consequence, ADAMTS16 lacks activity and can no longer effectively C-
terminally process itself. Another explanation could be the absence of the proteinase responsible for C-
terminal truncation of ADAMTS16 in COS-7 cells. This theory is plausible because ADAMTS4 has been 
shown to be C-terminally processed by MMP17 171 and it is therefore likely that either MMP17 or another 
membrane bound MMP also processes ADAMTS16. It is possible that COS-7 cells do not express the 
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proteinase responsible for C-terminal ADAMTS16 processing. Due to the fact that co-expression of 
ADAMTS16 and MMP14 in COS-7 cells did not lead to an increase in C-terminal truncation of ADAMTS16, 
as observed by western blot analysis, we can conclude that at least MMP14 is not responsible for 
ADAMTS16 processing. Additionally the binding partner for ADAMTS16 on the cell surface or within the 
ECM could be missing in COS-7 cells so that ADAMTS16 is secreted, but cannot bind in close proximity to 
the cell surface and is therefore not efficiently C-terminally processed.  
 
Our first attempt to find substrates for ADAMTS16 was by phage display. Therefore we used a 
commercially available phage library. The variety of potential substrates was rather limited and also the 
overall coverage of the consensus sequence with the target sequence of the potential ADAMTS16 binders 
was rather low. A reason for this can be that the peptides presented by the phages are only 7 amino acids 
long and do not contain any secondary structural elements. This can of course decrease the chance of 
finding any potential substrates, because substrate binding may require certain structural elements such 
as helixes and more than 7 amino acids in length. It is worth mentioning that especially the extracellular 
proteoglycans and glycoproteins identified in the phage display as potential binders share the same 
overlapping sequence with the consensus sequence. A lot of ECM glycoproteins and proteoglycans share 
common structural features, which allow them to interact with each other or bind to cell surface 
receptors. Thus it could be a coincidence that these binders were found in the screen and they might not 
be real substrates or binders of ADAMTS16. This is further supported by the fact that only 3 amino acids 
of the overall consensus sequence do overlap with the target sequence. On the other hand, we found 
ADAMTS16 to be co-localized with laminin and FN within the ECM. Additionally we even identified FN as 
a substrate of ADAMTS16. It is therefore possible that ADAMTS16 binds to FN and laminin via the 
identified target sequence. Additionally previous work showed that a truncated version of ADAMTS16 
only containing its protease domains, can bind and cleave aggrecan in vitro 154. Also neurocan is a likely 
target of ADAMTS16 because of its strong localization within the brain matrix, similar to ADAMTS16. 
Summarizing those findings, ADAMTS16 was shown to bind at least three of the glycoproteins and 
proteoglycans identified in the phage display screen and it is therefore possible that these proteins share 
this common structural feature to bind ADAMTS16 and or other members of the ADAMTS family.  
We decided to analyze MMP14 further since it showed strong coverage with the consensus sequence 
identified and literature indicates that it is often expressed during processes also involving ADAMTS16, 
such as osteoarthritis (OA), esophageal squamous cell carcinoma and during kidney and testis 
development 221, 222, 227, 228, 233-235. By analyzing the cell lysate of co-expressing cells, using an antibody 
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against the N-terminus of MMP14, the reduction of a lower molecular size band could be observed. 
However, no real reduction in full length MMP14 was observed. Additionally we observed a high 
molecular size band when analyzing the cell lysate with an antibody against the C-terminal HA-tag of 
MMP14 in combination with inactive ADAMTS16-EA and ADAMTS16-EA-sh. Because we could not observe 
the same effect using an antibody against ADAMTS16, we can conclude that it is not a complex of 
ADAMTS16-EA and MMP14. Especially because the band is also observed when MMP14 is expressed 
alone. It is however, likely that MMP14 forms a complex with another protein and upon cleavage by 
ADAMTS16 this complex formation is no longer possible. It would require further investigations, mainly 
using mass spectrometry, to decide whether it is a MMP14-protein complex, or an oligomerization of 
MMP14 alone. Analysis of MMP14 activity did not show any changes in the presence or absence of 
ADAMTS16. This indicates that cleavage of MMP14 by ADAMTS16 has no influence on its activity. Another 
reason for this observation might be that ADAMTS16 can indeed activate MMP14 but due to the fact that 
MMP14 is also activated by other proprotein convertases such as furin, MMP14 is already efficiently 
activated in the used cell systems and the presence of ADAMTS16 does not add to this process in a closed 
cellular in vitro system. However, studies on MMP14 activity showed that the kidneys of MMP14 null mice 
had increased deposition of collagen IV, laminin, perlecan, and nidogen and this phenotype was 
independent of MMP14 mediated MMP2 activation 233.  
Activation of proteinases in vivo is usually much more complex compared to a single cell in vitro system. 
Although the processing of the propetide is one of the key steps in regulating proteinase activity, C-
terminal processing can also severely influence protease activity. Moreover, it strongly affects the 
specificity of a proteinase towards its substrates, as observed in a variety of ADAMTS family members. 
Therefore it is likely that MMP14 processing by ADAMTS16 still influences the activity and or substrate 
specificity of MMP14 without affecting MMP2 activity. 
We also investigated whether ADAMTS16 can influence MMP3 activity directly and not only upregulate 
its expression. Unlike MMP14 which is a transmembrane proteinase, MMP3 is fully secreted. Therefore 
we analyzed the conditioned medium of HEK-EBNA cells co-expressing MMP3 and ADAMTS16. In the 
presence of active ADAMTS16 a reduction in the band corresponding to MMP3 is visible. However, no 
cleavage products were identified. A possible explanation for this is that the cleavage products are too 
small or their concentration is too low to be detected. Another explanation could be that MMP3 is 
activated and binds to the ECM, which leads to a clearance of soluble MMP3 from the conditioned 
medium. It would be necessary to analyze the cell free ECM of those cells to see whether there is an 
accumulation of MMP3 in the ECM of cells co-expressing MMP3 with active ADAMTS16. It is also likely 
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that the expression level of MMP3 in the presence of active ADAMTS16 is simply lower, because the cells 
are forced to overexpress two fully active proteinases.  
In a further attempt, purified ADAMTS16-sh was incubated with the conditioned medium containing 
MMP3. Although we observed a second band in the presence of active ADAMTS16-sh the bands were not 
clearly separated, but appeared as smeared double bands. This effect could also be observed in the 
presence of the metalloproteinase inhibitor EDTA. However, this effect is not correlated to the presence 
of EDTA but to ADAMTS16-sh. Because the experiment was repeated several times, yielding the same 
result, a technical mistake is unlikely. Nevertheless there is a possibility that EDTA does not completely 
inhibit ADAMTS16-sh and that even in its presence, there is a slight degradation of MMP3.  
We further analyzed the concentrated medium of MDCKI cells stably expressing ADAMTS16 for MMP3 
activity by casein zymography. Casein zymography, although extensively used in various publications, is 
not the ideal way to determine MMP3 activity. We found that in the presence of active ADAMTS16 the 
overall amount of MMP3 is increased. This is not surprising because analysis of the mRNA in this cells 
showed an increase in MMP3 expression in the presence of active ADAMTS16. However, we observed an 
accumulation of inactive MMP3 in the conditioned medium of cells expressing inactive ADAMTS16-EA. 
ADAMTS16-EA most likely binds to MMP3 but is not capable to further process it. Moreover, due to its 
binding, ADAMTS16-EA prevents MMP3 from being processed by other proteinases as well. Thus keeping 
it in its zymogen form.  
 
Because ADAMTS16 was already described to have a role in various diseases and during development, we 
analyzed a variety of cancer cell lines as well as embryonal tissue for ADAMTS16 expression. We found 
ADAMTS16 to be expressed in various cancer cell lines. It has to be noted that we analyzed cultured cell 
lines and no standard control could be used in this work. Therefore one cannot conclude whether the 
expression of ADAMTS16 is abnormal in those cell lines. We also analyzed the RNA of total human brain 
cell extract. There we found relative high levels of endogenous ADAMTS16 expression, which is not  
surprising because previous studies already reported endogenous ADAMTS16 expression in human adult 
brain 236. However, also this is not an ideal base level to access whether the expression levels of ADAMTS16 
in the investigated brain tumor cell lines are down respectively upregulated. For this it would be necessary 
to figure out the exact cell types of the brain that are expressing ADAMTS16. To gain a better 
understanding whether ADAMTS16 is upregulated during tumor progression a bigger collection of 
samples would be needed and these would need to be compared to healthy tissue.  
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We further analyzed the expression of ADAMTS16 during development. Because previous publications 
reported a correlation of ADAMTS16 and kidney development and branching 219, 220 we had a closer look 
at Adamts16 expression in mouse embryonal as well as adult kidney tissue. We observed that Adamts16 
expression starts at very early developmental time points (E10.5) and remains high until birth. Although 
the expression of Adamts16 remains high shortly after birth and during the adolescence of the mice, 
expression levels of Adamts16 are massively reduced in adult tissue of fully grown mice. This suggests that 
ADAMTS16 is required during organ development and might participates in ECM remodeling during organ 
growth. However, after the organ is fully grown the expression of Adamts16 is significantly reduced and 
strongly localized around and within cells of the glomeruli, where it is most likely involved in the 
maintenance of its basement membrane.    
 
To gain further insight into the cellular function of ADAMTS16 and its potential effects on cell behavior, 
we performed a couple of functional assays, such as cell proliferation and migration assays and also had 
a closer look at filopodia formation in ADAMTS16 expressing cells. Filopodia are actin-rich plasma 
membrane protrusions that allow cells to probe their environment. Therefore filopodia have an important 
role in cell migration, wound healing and neurite outgrowth. Additionally filopodia are involved in cell 
adhesion to the ECM 237. The ECM plays a major role during filopodia development mainly via the 
activation of small GTPases of the Rho superfamily 238. Studies showed that cell signaling via the ECM can 
activate CDC42, which subsequently leads to increased filopodia formation 239. Interestingly integrins 
accumulate in filopodia. Via the integrin receptors, filopodia can probe the matrix along the leading edge 
that promotes cell adhesion and migration 237. During cell spreading, integrin-containing filopodia form 
the initial adhesion sites. Subsequently other focal adhesion complex proteins, such as talin, paxillin and 
FAK, are recruited to these sites to form mature focal adhesions 240. This is interesting because ADAMTS16 
was shown in our studies to degrade FN and therefore most likely subsequently prevents FN-integrin 
binding and filopodia development. In the presence of active ADAMTS16 the surrounding FN is digested, 
something that potentially influences filopodia formation. In the absence of FN, integrin mediated 
filopodia-FN interactions can no longer occur and the formation of mature focal adhesions might be 
inhibited. Indeed we observed a reduction of filopodia formation in HEK-EBNA cells expressing 
wtADAMTS16 when seeded on a FN coated surface. Cells expressing inactive ADAMTS16-EA, however, 
showed strong filopodia development when seeded on a FN coated surface. Because FN-integrin 
interactions and consequently filopodia formation are the first steps in the development of mature focal 
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adhesion, it would be necessary to further investigate the effect of ADAMTS16 on focal adhesions and 
subsequently on the regulation of FAK and Rho mediated pathways. 
 
The expression of proteinases especially members of the MMP family often lead to an increased migratory 
behavior of cancer cells, but also of epithelial cells during development. Additionally a variety of ADAMTS 
family members have been associated with an increased migratory behavior during development and 
disease 241, 242. Therefore we aimed at testing whether ADAMTS16 expression can increase cell migration. 
Thus we used HEK-EBNA cells and the epithelial cell line MDCKI. MDCKI cells stably expressing active 
ADAMTS16 and ADAMTS16-sh showed stronger migration compared to cells expressing vector or inactive 
mutant controls. However, on untreated filters HEK-EBNA cells did not show any migration at all. Several 
publications stated that coating the underside or both sides of the Boyden chamber filter membrane with 
FN can facilitate and increase cell migration in a variety of cell types 243. Therefore the lower filter side of 
the Boyden chamber was coated with FN and the migration of MDCKI and HEK-EBNA cells stably 
expressing ADAMTS16 was analyzed again. The epithelial cell line MDCKI showed no significant 
differences between the migration on coated and untreated filters could be observed. However, HEK-
EBNA cells migrated significantly more on FN coated filters. Moreover, cells expressing wtADAMTS16 
showed a massively increased migration. Interestingly, also cells expressing the inactive full length mutant 
ADAMTS16-EA showed an increased migration compared to vector control or cells expressing the 
truncated inactive mutant ADATMS16-sh-EA. This leads to the conclusion that the C-terminus can 
influence the migratory potential independent of catalytic activity, at least in HEK-EBNA cells. Why these 
cells migrate more on coated filters remains unclear. FN however can act as a chemoattractant and/or 
adhesive molecule. Cells might migrate towards FN, which allows them a better adhesion. Due to the fact 
that cells expressing an active ECM proteinase most likely already have a lower overall adhesion due to 
the proteolytic decrease of adhesive proteins, this might be a possible explanation why HEK cells stably 
expressing wtADAMTS16 migrate stronger towards FN. However, there is the possibility that upon FN 
coating a lot of ECM bound chemoattractants can bind to FN and the cells migrate along this gradient. 
Again due to the ECM remodeling capacities of ADAMTS16, cells expressing wtADAMTS16 migrate faster. 
Whether FN is a chemoattractant itself or binds chemoattractants would need further investigations.    
In a last assay we investigated the effect of ADAMTS16 on cell proliferation.  ADAMTS16 did not influence 
cell proliferation in MDCKI cells, however, the proliferation of wtADAMTS16-expressing LN229 cells was 
massively reduced compared to vector control or cells expressing the inactive mutant. The reduced 
proliferation of LN229 cells expressing wtADAMTS16 is most likely due to the reduction of FN within their 
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matrix. Increased FN expression has been previously linked to increased cell proliferation during tumor 
growth as well as in developmental processes 244-246. Consequently it was shown that the knockdown of 
FN in the colorectal cancer cell line SW480 led to reduced cell proliferation 241. Therfore we can conclude 
that excessive expression of ADAMTS16 in LN229 cells and the correlated decrease in matrix FN through 
ADAMTS16 mediated digestion, results in decreased cell proliferation. MDCKI cells however do produce 
FN in 2D cell layers, but they do not assamble FN into large fibres as observed for LN229 cells or fibroblasts. 
This could be an explanation for the fact that no differences in cell proliferation of MDCKI cells expressing 
wtADAMTS16 or ADAMTS16-EA could be observed.  
Interestingly in 3D spheroid morphogenesis assays using MDCKI cells, the inactive ADAMTS16-EA led to a 
strong accumulation of FN in their matrix. This is most likely due to the binding and protection of 
ADAMTS16 to fibronectin. The binding of ADAMTS16-EA can therefore prevent either other proteinases 
from binding to FN and/or protect the proteolytcaly sensitve linker domain of FN from proteolytic 
cleavage. The resulting increase in FN in the matrix can have other effects, such as increased matrix 
stiffness and activation of FN-integrin dependent pathways, such as the phosphorylation of FAK and the 
consequent activation of the Rho/Rock pathway. Further investigations addressing these pathways would 
be needed.  
The observed effect of inactive ADAMTS16-EA is especially interesting because a variety of papers report 
not only that mutations in the ADAMTS16 gene have severe influences on blood pressure regulation 227, 
but also lead to reduced metastasis and cell growth in ovarien cancer 229. Altough ADAMTS16 knockouts 
were done to investiate the effect of ADAMTS16 on blood pressure regulation, it is most likely not enough 
to fully understand the complexity of ADAMTS16 in regard of blood pressure regulation and cancer 
metastasis. As shown by our studies, it would be worthwhile having a closer look at the mutations 
themselves and address the question whether or not these mutations influence the activity and cellular 
localization of ADAMTS16. Subsequently a study addressing the composition and stiffness of the tissue, 
especially in regard to FN accumulation and the resulting downstream signalling cascades would be 
needed. As our results showed a simple knockout is not enough to address the complex function of 
ADAMTSs in regulating cellular functions, especially with respect to ADAMTS16. Many ADAMTS, as well 
as MMP or ADAM knockout animals do not show a specific phenotype. This is not surprising considering 
the complexity and importance of ECM remodelling during development. Morover, the lack of a certain 
proteinase can easely be compensated for by the activity of a closely related family member with similar 
substrate specificity. However, overexpression of a variety of proteinases has severe consequences and 
leads to the development of a variety of diseasees such as OA, cancer or tissue fibrosis. Interestingly the 
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study of Yasukawa et al. regarding therapeutic outcome and overall survival of ovarien cancer patients 
showed that it is not so much a matter of ADAMTS16 expression itself, but whether certain missense 
mutations occur within the ADAMTS16 gene. Cancer cells expressing wtADAMTS16 showed a stronger 
migration and invasive behaviour compared to tumor cells expressing mutant ADAMTS16. Mutant 
ADAMTS16 expressing cells even showed a reduced migration and invasion compared to vector control 
tumor cells. Indicating that the mutations are not simply loss of function mutations, but that the protein 
can, although mutated, still inflence cell signalling and cancer progression. Interestingly none of the 
identified mutations were in the catalytic domain, but rather within the C-terminal TSR1 domains or the 
PLAC domain. Our studies clearly showed that these domains have functional roles in ECM binding and 
most likely substrate recognition. Further ADAMTS16 is strongly C-terminally processed, which is most 
likely a form of activity regulation. Mutations in these domains therefore can have severe consequences 
in regard to substrate specificity or activity. The sudy of these mutations and their functional effects could 
open a variety of possibiliies with respect to  personalized therapy. Moreover, studying them would also 
give a better understanding of the biochemical and biological function of single domains within the 
protein.   
 
The identification of FN as a substrate of ADAMTS16 opens a variety of possibilities on how to further 
progress with the research in this area. Especially the fact that ADAMTS16 can influence tissue stiffness 
thereby having  important regulatory influences on several pathways such as FAK phosphorylation and 
activation of the Rho/Rock pathway provides a variety of new interesting insights into proteinase function. 
Additionally the potential of ADAMTS16 in influencing the activety of several members of the MMP family 
should be further investigated. This would give further insights into the protease web and would increase 
our understanding of the complex regulation of protease activity and function. A better understanding of 
the close interplay of proteinases and the resulting changes in activity can lead to a better understanding 
of diseases such as cancer and OA and can lead to the development of better and more efficient 
therapeutic agents. 
Extracellular proteinases have long been simply reduced to their function on ECM degradation, but studies 
addressing the changes in cell signaling upon protein cleavage remain limited. The ECM itself has long 
been neglected and thought of as a simple scaffold for cell adhesion and or as barrier for cell migration 
without further influence on cell signaling and behavior. However recent work focusing on tissue 
mechanics and engineering, showed that the composition of the ECM and its stiffness tremendously 
influences cell signaling. The tissue composition guides stem cell differentiation as well as cancer relapse 
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after radiation therapy 247, 248. The ECM also acts as barrier and absorbent of a variety of chemo-
therapeutic agents and antibodies, which makes cancer treatment so challenging. Therefore a better 
understanding of the function of extracellular proteinases and how they influence tissue mechanics can 
lead to a better understanding of disease mechanisms and lead to the development of more efficient 
therapies.   
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8. Appendix 
 
8.1 Supplementary Figures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1: Vectors used for ADAMTS16 and MMP14 gene transfer. A. pCEP-pu expression 
vector. Myc_His6-tag was added to ADAMTS16 genes and ADAMTS16-Myc_His6 was cloned into the pCEP-
pu vector. pCEP-pu_ ADAMTS16-Myc_His6 was used for stable transfection of HEK-EBNA cells and MDCKI 
cells and transient transfection of COS-7 and LN229 cells. B. pcDNA3.1 expression vector. HA-tag was 
added to the C-terminus of MMP14 and MMP14-HA was cloned into pcDNA3.1vector. 
pcDNA3.1_MMP14-HA was used to transiently transfect COS-7 cells.   
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Supplementary Figure 2: Protein alignment of the used mouse ADAMTS16 constructs. The 
mouse_ADAMTS16 sequence corresponds to the wild type ADAMTS16 sequence (UniProt accession 
number Q69Z28). The active site mutant E432/A432 is marked in red. The last amino acid of the C-
terminally truncated ADAMTS16-sh is marked in yellow. Additionally the furin cleavage site, the first C-
terminal TSR1 motif (TSR type-1 2) and the PLAC domain are annotated.     
 
  
Furin cleavage site 
Active site mutation E432/A432 
Last amino acid of truncated ADAMTS16-sh 
TSR type-1 2 
PLAC domain 
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Supplementary Figure 3: The Universal Protein Resource (UniProt) protein alignment of FN. Alignment 
starts at the N-terminal signal peptide until fibronectin type-III 1 domain. Signal peptides at the N-
terminus (orange), the N-terminal ADAMTS16 cleavage site leading to the release of the 30 kDa N-terminal 
heparin binding domain of FN (P1/P1’, red) and the second potential ADAMTS16 cleavage site identified 
by MS (P1/P1’, yellow) are annotated.   
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Supplementary Figure 4: In-gel digest and protein identification of co-purified proteins during 
ADAMTS16-sh purification. Scaffold data supplementing the discussed results in chapter 5.2.1 
“ADAMTS16 is C-terminally processed and forms high order oligomers”.  
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8.2 Abbreviations  
 
- ADAM  A Disintegrin and Metalloproteinase 
- ADAMTS A Disintegrin and Metalloproteinase with Thrombospondin motifs  
- ADAMTSL ADAMTS-like protein 
- APP  Amyloid precursor protein 
- BM   Basement membrane  
- C-terminus Carboxy-terminus 
- Col  Collagen 
- CLUS  Clusterin 
- DOC   Deoxycholate 
- ECM   Extracellular matrix  
- EGF  Epidermal growth factor  
- EGFR  Epidermal growth factor receptor  
- EMMPRIN Extracellular matrix metalloproteinase inducer 
- FAK  Focal adhesion kinase 
- FBN  Fibrillin 
- FGF  Fibroblast growth factors 
- FN   Fibronectin 
- GAG  Glycosaminoglycan  
- HA  Hyaluronan 
- HB-EGF Heparin-binding epidermal growth factor   
- HSP71  Heat shock 70 kDa protein 1A/1B 
- IGF  Insulin-like growth factor 
- IEL  Isolated ectopia lentis 
- LRP  Low-density lipoprotein-related protein 
- MMP  Matrix metalloproteinase  
- MS  Mass spectrometry 
- N-terminus Amino-terminus 
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- OA  Osteoarthritis  
- PG  Proteoglycan 
- PLAC   Protease and lacunin  
- SH3 domain Src-homology 3 domain 
- SLRP  Small leucine-rich proteoglycans 
- TGF-β  Transforming growth factor-β 
-TIMP  Tissue Inhibitors of Metalloproteinases 
- TN   Tenascin  
- TNF-α  Tumor necrosis factor-α 
- TGN  Trans-Golgi network 
- TSR  Thrombospondin type 1 motif 
- TTP   Thrombotic thrombocytopenic purpura 
-VEGF  Vascular endothelial growth factor 
- vWF  Von Willebrand Factor 
-Wt1  Wilms tumor protein  
 
  
